{
    "0093175a-38cb-4f63-b391-709ac48158b8": {
        "Section_id": "eligibility",
        "Statement": "Patients with tumors overexpressing HER-2 are eligible for the secondary trial, but not for the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "DISEASE CHARACTERISTICS:",
            "  Histologically confirmed adenocarcinoma of the breast",
            "  Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC",
            "  Stage IV disease",
            "  Must not be eligible for therapy of known curative potential for metastatic breast cancer",
            "  Measurable or evaluable disease",
            "  Stable CNS disease allowed provided that it's adequately treated and not under active treatment",
            "  Hormone receptor status not specified",
            "  PATIENT CHARACTERISTICS:",
            "  Menopausal status not specified",
            "  ECOG performance status 0-1",
            "  ANC > 1,000/mm^3",
            "  Platelets > 100,000/mm^3",
            "  Serum bilirubin < 2.0 mg/dL (unless due to Gilbert syndrome)",
            "  AST and ALT < 2 times upper limit of normal (ULN)",
            "  Alkaline phosphatase < 5 times ULN",
            "  Serum creatinine < 2.0 mg/dL",
            "  Ejection fraction normal by MUGA OR  50% by echocardiogram",
            "  Not pregnant or nursing",
            "  Fertile patients must use effective contraception",
            "  HIV negative",
            "  Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed",
            "  No prior or concurrent autoimmune disease requiring management with systemic immunosuppression, including any of the following:",
            "  Inflammatory bowel disease",
            "  Systemic vasculitis",
            "  Scleroderma",
            "  Psoriasis",
            "  Multiple sclerosis",
            "  Hemolytic anemia or immune-mediated thrombocytopenia",
            "  Rheumatoid arthritis",
            "  Systemic lupus erythematosus",
            "  Sjogren syndrome",
            "  Sarcoidosis",
            "  Other rheumatologic disease",
            "  No other malignancies within the past 5 years, except carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, superficial bladder cancer, or tamoxifen-related endometrial cancer that has been adequately treated",
            "  No active major medical or psychosocial problems that could be complicated by study participation",
            "  No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest",
            "  No uncontrolled medical problems",
            "  No evidence of active acute or chronic infection",
            "  No known severe hypersensitivity to trastuzumab, except mild to moderate infusion reactions that are easily managed and do not recur",
            "  No allergy to corn",
            "  PRIOR CONCURRENT THERAPY:",
            "  See Disease Characteristics",
            "  More than 28 days since prior and no other concurrent chemotherapy, radiation therapy, or biologic therapy (except trastuzumab)",
            "  Concurrent endocrine therapy and supportive therapy with bisphosphonates allowed",
            "  More than 28 days since prior and no other concurrent participation in an investigational new drug trial",
            "  More than 28 days since prior and no other concurrent systemic oral steroids",
            "  Topical, ocular, and nasal steroids allowed",
            "  No prior vaccination with the allogeneic GM-CSF-secreting breast tumor vaccine"
        ],
        "Secondary_CT": [
            "Inclusion Criteria:",
            "  Female patients with histologically confirmed adenocarcinoma of the breast or inflammatory breast cancer",
            "  Clinical stage T 1-4, N 0-3, M0",
            "  FISH+ HER2 gene amplified breast cancer",
            "  18 years or older",
            "  Normal cardiac function",
            "  Performance status 0-2",
            "  Cannot have received any prior chemotherapy for this disease or cannot have received chemotherapy for any other cancer in the past 5 years.",
            "  Previous diagnosis of noninvasive breast cancer is OK.",
            "  Must have adequate bone marrow, renal and liver function.",
            "  Pregnant or lactating females not allowed.",
            "  Preexisting peripheral neuropathy must be equal to or less than grade 1",
            "  Must have archived tumor tissue for tissue testing.",
            "Exclusion Criteria:",
            "  You cannot be in this study if you any of the following:",
            "  History of cardiac disease, with New York Heart Association Class II or greater with congestive heart failure",
            "  Any heart attack, stroke or TIAs within the last 6 months or serious arrhythmias needing medication; no bleeding diathesis or coagulopathy.",
            "  No prior investigational drug within the last 30 days",
            "  No prior trastuzumab or bevacizumab therapy",
            "  There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons."
        ]
    },
    "0e3c62f7-a152-4370-9d09-b69a715c0a21": {
        "Section_id": "intervention",
        "Statement": "the secondary trial and the primary trial are evaluating surgical interventions for breast reconstruction for patients that have had mastectomies.",
        "Label": "Contradiction",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  Nipple Reconstruction Cylinder",
            "  Nipple reconstruction: Biodesign\u00ae Nipple Reconstruction Cylinder"
        ],
        "Secondary_CT": [
            "INTERVENTION 1: ",
            "  Arm 1: BREASTChoice (Decision Tool)",
            "  Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.",
            "INTERVENTION 2: ",
            "  Arm 2: Enhanced Usual Care (Surgical Care Booklet)",
            "  Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet \"Breast Reconstruction.\" They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes."
        ]
    },
    "0f49a1ec-ed73-465b-be20-b70fe990b1f0": {
        "Section_id": "adverse_events",
        "Statement": "There are several coagulative adverse events recorded in the primary trial, but not a single one in the secondary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 82/217 (37.79%)",
            "  Febrile neutropenia 21/217 (9.68%)",
            "  Neutropenia 4/217 (1.84%)",
            "  Leukopenia 0/217 (0.00%)",
            "  Anaemia 1/217 (0.46%)",
            "  Thrombocytopenia 0/217 (0.00%)",
            "  Atrial fibrillation 0/217 (0.00%)",
            "  Arrhythmia 1/217 (0.46%)",
            "  Arteriospasm coronary 0/217 (0.00%)",
            "  Atrioventricular block first degree 0/217 (0.00%)",
            "  Cardiac failure 0/217 (0.00%)",
            "Adverse Events 2:",
            "  Total: 106/252 (42.06%)",
            "  Febrile neutropenia 29/252 (11.51%)",
            "  Neutropenia 13/252 (5.16%)",
            "  Leukopenia 3/252 (1.19%)",
            "  Anaemia 0/252 (0.00%)",
            "  Thrombocytopenia 1/252 (0.40%)",
            "  Atrial fibrillation 1/252 (0.40%)",
            "  Arrhythmia 0/252 (0.00%)",
            "  Arteriospasm coronary 1/252 (0.40%)",
            "  Atrioventricular block first degree 1/252 (0.40%)",
            "  Cardiac failure 1/252 (0.40%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 6/40 (15.00%)",
            "  Nausea 1/40 (2.50%)",
            "  Vomiting 1/40 (2.50%)",
            "  Chest pain 1/40 (2.50%)",
            "  Hypercalcemia 1/40 (2.50%)",
            "  Thromboembolism 2/40 (5.00%)"
        ]
    },
    "135311d8-c579-4568-913e-937be00dde7e": {
        "Section_id": "results",
        "Statement": "In both the secondary trial and the primary trial the test cohorts achieved better overall response than the control groups.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Outcome Measurement: ",
            "  Progression-free Survival (PFS)",
            "  PFS was defined as the interval from study entry until disease progression or death resulting from any cause, which ever occurred first. Progression is defined as a 20% increase in the sum of longest diameter of target lesions (per RECIST criteria).",
            "  Time frame: Interval from randomization until disease progression or death, whichever occurs first, assessed up to 5 years",
            "Results 1: ",
            "  Arm/Group Title: Arm I (Lapatinib)",
            "  Arm/Group Description: Patients receive 1500 mg lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg)of each subsequent course.",
            "  Overall Number of Participants Analyzed: 146",
            "  Median (95% Confidence Interval)",
            "  Unit of Measure: months  4.7        (3.7 to 5.7)",
            "Results 2: ",
            "  Arm/Group Title: Arm II (Placebo)",
            "  Arm/Group Description: Patients receive placebo PO QD on days 1-28 and fulvestrant IM on days 1 (500 mg) and 15 (250 mg) of course 1 and on day 1 (250 mg) of each subsequent course.",
            "  Overall Number of Participants Analyzed: 145",
            "  Median (95% Confidence Interval)",
            "  Unit of Measure: months  3.8        (3.8 to 5.6)"
        ],
        "Secondary_CT": [
            "Outcome Measurement: ",
            "  Number of Participants With Overall Response (OR), Defined as Those Participants Achieving Complete Response (CR) or Partial Response (PR), Assessed Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 and Cutaneous Lesions",
            "  RECIST-based response assessment was done at Weeks (Wks) 4 and 8 and every 8 weeks thereafter. Cutaneous disease assessment was done at Wk 4 and every 4 weeks thereafter. OR was evaluated when the skin and RECIST assessments coincided. Per RECIST, CR is the disappearance of all target and non-target lesions; PR is at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions, taking as a reference the baseline sum LD. Cutaneous disease contained non-measurable and measurable skin disease, which was assessed by skin assessment tools.",
            "  Time frame: Baseline until disease progression/recurrence was documented, assessed for up to 66 weeks",
            "Results 1: ",
            "  Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib Placebo",
            "  Arm/Group Description: Participants received oral lapatinib 1500 milligrams (mg) (6 x 250 mg tablets) in combination with placebo (matching to pazopanib; 2 tablets) once daily (QD).",
            "  Overall Number of Participants Analyzed: 38",
            "  Measure Type: Number",
            "  Unit of Measure: participants  11",
            "Results 2: ",
            "  Arm/Group Title: Cohort 1: Lapatinib 1500 mg + Pazopanib 800 mg",
            "  Arm/Group Description: Participants received oral lapatinib 1500 mg (6 x 250 mg tablets) in combination with pazopanib 800 mg (2 x 400 mg tablets) QD.",
            "  Overall Number of Participants Analyzed: 38",
            "  Measure Type: Number",
            "  Unit of Measure: participants  17"
        ]
    },
    "14a5e557-b223-4649-9867-0ff0e9001f5e": {
        "Section_id": "intervention",
        "Statement": "the primary trial and the secondary trial do not explain their interventions in the intervention section.",
        "Label": "Contradiction",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  MM-111",
            "All participants"
        ],
        "Secondary_CT": [
            "INTERVENTION 1: ",
            "  Arm I (Low-dose Omega-3 Fatty Acid)",
            "  Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.",
            "Omega-3 Fatty Acid: Given PO",
            "  Placebo: Given PO",
            "  Questionnaire Administration: Ancillary studies",
            "  Laboratory Biomarker Analysis: Correlative studies",
            "INTERVENTION 2: ",
            "  Arm II (High-dose Omega-3 Fatty Acid)",
            "  Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.",
            "Omega-3 Fatty Acid: Given PO",
            "  Questionnaire Administration: Ancillary studies",
            "  Laboratory Biomarker Analysis: Correlative studies"
        ]
    },
    "15553950-e26b-4fbb-a576-8455e6bb7b23": {
        "Section_id": "intervention",
        "Statement": "The intervention section for the primary trial does not detail the type, dosage or duration of the intervention, unlike the secondary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  Patients Undergoing Mastectomy Surgery",
            "  Number of individuals having mastectomy surgery who were approached for participation in the trial"
        ],
        "Secondary_CT": [
            "INTERVENTION 1: ",
            "  Treatment (Tivantinib)",
            "  Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.",
            "  Laboratory Biomarker Analysis: Correlative studies",
            "  Tivantinib: Given PO"
        ]
    },
    "1739541a-2d3f-4a13-b956-769a1cbed4d7": {
        "Section_id": "adverse_events",
        "Statement": "1 patient in cohort 1 of the primary trial was diagnosed with a Clear cell renal cell carcinoma.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 2/60 (3.33%)",
            "  Bronchial infection 0/60 (0.00%)",
            "  Ankle fracture 1/60 (1.67%)",
            "  Clear cell kidney cancer 0/60 (0.00%)",
            "  Programmed peritoneal dialysis 1/60 (1.67%)",
            "  Endometrial atrophy 0/60 (0.00%)",
            "Adverse Events 2:",
            "  Total: 3/58 (5.17%)",
            "  Bronchial infection 1/58 (1.72%)",
            "  Ankle fracture 0/58 (0.00%)",
            "  Clear cell kidney cancer 1/58 (1.72%)",
            "  Programmed peritoneal dialysis 0/58 (0.00%)",
            "  Endometrial atrophy 1/58 (1.72%)"
        ]
    },
    "1aee22c7-96f2-4ea6-909a-48741f87ba07": {
        "Section_id": "adverse_events",
        "Statement": "There were no observed cases of Constipation, Diarrhoea, Nausea or Febrile neutropenia within patient cohorts 1 and 2 of the primary trial.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 3/8 (37.50%)",
            "  Anaemia 0/8 (0.00%)",
            "  Febrile neutropenia 0/8 (0.00%)",
            "  Polycythaemia 0/8 (0.00%)",
            "  Acute coronary syndrome 0/8 (0.00%)",
            "  Vertigo 0/8 (0.00%)",
            "  Eyelid oedema 1/8 (12.50%)",
            "  Constipation 0/8 (0.00%)",
            "  Diarrhoea 0/8 (0.00%)",
            "  Nausea 0/8 (0.00%)",
            "  Stomatitis 0/8 (0.00%)",
            "  Upper gastrointestinal haemorrhage 0/8 (0.00%)",
            "  Vomiting 0/8 (0.00%)",
            "  Chest pain 0/8 (0.00%)",
            "Adverse Events 2:",
            "  Total: 2/6 (33.33%)",
            "  Anaemia 0/6 (0.00%)",
            "  Febrile neutropenia 0/6 (0.00%)",
            "  Polycythaemia 0/6 (0.00%)",
            "  Acute coronary syndrome 0/6 (0.00%)",
            "  Vertigo 0/6 (0.00%)",
            "  Eyelid oedema 0/6 (0.00%)",
            "  Constipation 0/6 (0.00%)",
            "  Diarrhoea 0/6 (0.00%)",
            "  Nausea 0/6 (0.00%)",
            "  Stomatitis 0/6 (0.00%)",
            "  Upper gastrointestinal haemorrhage 0/6 (0.00%)",
            "  Vomiting 0/6 (0.00%)",
            "  Chest pain 1/6 (16.67%)"
        ]
    },
    "2417fea2-7c8e-4f03-a918-c3cfcbe97425": {
        "Section_id": "adverse_events",
        "Statement": "The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 18/115 (15.65%)",
            "  Febrile neutropenia * 7/115 (6.09%)",
            "  Neutropenia * 1/115 (0.87%)",
            "  Pancytopenia * 1/115 (0.87%)",
            "  Diarrhoea * 0/115 (0.00%)",
            "  Nausea * 0/115 (0.00%)",
            "  Stomatitis * 0/115 (0.00%)",
            "  Vomiting * 1/115 (0.87%)",
            "  Asthenia * 1/115 (0.87%)",
            "  Mucosal inflammation * 0/115 (0.00%)",
            "  Pyrexia * 3/115 (2.61%)",
            "  Gastrointestinal infection * 1/115 (0.87%)",
            "Adverse Events 2:",
            "  Total: 8/112 (7.14%)",
            "  Febrile neutropenia * 3/112 (2.68%)",
            "  Neutropenia * 2/112 (1.79%)",
            "  Pancytopenia * 0/112 (0.00%)",
            "  Diarrhoea * 2/112 (1.79%)",
            "  Nausea * 2/112 (1.79%)",
            "  Stomatitis * 1/112 (0.89%)",
            "  Vomiting * 1/112 (0.89%)",
            "  Asthenia * 0/112 (0.00%)",
            "  Mucosal inflammation * 1/112 (0.89%)",
            "  Pyrexia * 0/112 (0.00%)",
            "  Gastrointestinal infection * 0/112 (0.00%)"
        ]
    },
    "3129e58d-0c16-42a5-90b4-f26e048dfe58": {
        "Section_id": "adverse_events",
        "Statement": "Throughout the primary trial, one patient in cohort 1 developed issues with their vision.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 34/214 (15.89%)",
            "  Leukocytosis 0/214 (0.00%)",
            "  Atrial fibrillation 0/214 (0.00%)",
            "  Cardiac failure congestive 0/214 (0.00%)",
            "  Pericardial effusion 1/214 (0.47%)",
            "  Cataract 0/214 (0.00%)",
            "  Macular fibrosis 0/214 (0.00%)",
            "  Constipation 2/214 (0.93%)",
            "  Diarrhoea 2/214 (0.93%)",
            "  Enterocolitis 0/214 (0.00%)",
            "  Ileus 1/214 (0.47%)",
            "  Nausea 3/214 (1.40%)",
            "Adverse Events 2:",
            "  Total: 27/213 (12.68%)",
            "  Leukocytosis 1/213 (0.47%)",
            "  Atrial fibrillation 1/213 (0.47%)",
            "  Cardiac failure congestive 1/213 (0.47%)",
            "  Pericardial effusion 0/213 (0.00%)",
            "  Cataract 1/213 (0.47%)",
            "  Macular fibrosis 1/213 (0.47%)",
            "  Constipation 1/213 (0.47%)",
            "  Diarrhoea 1/213 (0.47%)",
            "  Enterocolitis 1/213 (0.47%)",
            "  Ileus 0/213 (0.00%)",
            "  Nausea 0/213 (0.00%)"
        ]
    },
    "34ee4f66-e6f7-458c-964c-12fa730a9d56": {
        "Section_id": "intervention",
        "Statement": "Both cohorts the primary trial apply the topical intervention for approximately every 4-6 hours every day for a week of the study.",
        "Label": "Entailment",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  Arm I (Curcumin-based Gel)",
            "  Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.",
            "Curcumin-based Gel: Applied topically",
            "  Laboratory Biomarker Analysis: Correlative studies",
            "  Questionnaire Administration: Ancillary studies",
            "INTERVENTION 2: ",
            "  Arm II (HPR Plus)",
            "  Patients apply HPR Plus\u2122 topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.",
            "  Dermatologic Complications Management: Apply HPR Plus topically",
            "  Laboratory Biomarker Analysis: Correlative studies",
            "  Questionnaire Administration: Ancillary studies"
        ]
    },
    "3948b30d-934d-485c-b324-b3571e2957a3": {
        "Section_id": "adverse_events",
        "Statement": "The most common adverse events in the primary trial and the secondary trial is Neutropenia with a total of 3 cases across all cohorts.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 267/744 (35.89%)",
            "  Neutropenia *2/744 (0.27%)",
            "  Anaemia *1/744 (0.13%)",
            "  Leukopenia *1/744 (0.13%)",
            "  Thrombocytopenia *1/744 (0.13%)",
            "  Thrombotic thrombocytopenic purpura *1/744 (0.13%)",
            "  Atrial flutter *1/744 (0.13%)",
            "  Cardiac arrest *1/744 (0.13%)",
            "  Myocardial ischaemia *1/744 (0.13%)",
            "  Arrhythmia *0/744 (0.00%)",
            "  Cardiac failure congestive *0/744 (0.00%)",
            "Adverse Events 2:",
            "  Total: 67/736 (9.10%)",
            "  Neutropenia *1/736 (0.14%)",
            "  Anaemia *0/736 (0.00%)",
            "  Leukopenia *0/736 (0.00%)",
            "  Thrombocytopenia *0/736 (0.00%)",
            "  Thrombotic thrombocytopenic purpura *0/736 (0.00%)",
            "  Atrial flutter *0/736 (0.00%)",
            "  Cardiac arrest *0/736 (0.00%)",
            "  Myocardial ischaemia *0/736 (0.00%)",
            "  Arrhythmia *2/736 (0.27%)",
            "  Cardiac failure congestive *1/736 (0.14%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 6",
            "  Atrial fibrillation 1/67 (1.49%)",
            "  Ventricular fibrillation 1/67 (1.49%)",
            "  Gastrointestinal perforation 1/67 (1.49%)",
            "  Periproctitis 1/67 (1.49%)",
            "  General physical health deterioration 1/67 (1.49%)",
            "  Escherichia sepsis 1/67 (1.49%)",
            "  Pneumonia 1/67 (1.49%)",
            "  Tumour pain 1/67 (1.49%)",
            "  Renal failure acute 1/67 (1.49%)",
            "  Pleurisy 1/67 (1.49%)"
        ]
    },
    "405369ef-d216-4d81-a04f-46f36f466a19": {
        "Section_id": "adverse_events",
        "Statement": "Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 5/26 (19.23%)",
            "  Febrile neutropenia 1/26 (3.85%)",
            "  Abdominal pain 0/26 (0.00%)",
            "  Constipation 0/26 (0.00%)",
            "  Nausea 1/26 (3.85%)",
            "  Pancreatitis 1/26 (3.85%)",
            "  Vomiting 2/26 (7.69%)",
            "  Pain 0/26 (0.00%)",
            "  Pneumonia 0/26 (0.00%)",
            "  Urinary tract infection 1/26 (3.85%)",
            "  Lumbar vertebral fracture 1/26 (3.85%)",
            "  Ammonia increased 1/26 (3.85%)",
            "  Hepatic encephalopathy 1/26 (3.85%)",
            "Adverse Events 2:",
            "  Total: 4/13 (30.77%)",
            "  Febrile neutropenia 1/13 (7.69%)",
            "  Abdominal pain 1/13 (7.69%)",
            "  Constipation 1/13 (7.69%)",
            "  Nausea 0/13 (0.00%)",
            "  Pancreatitis 0/13 (0.00%)",
            "  Vomiting 0/13 (0.00%)",
            "  Pain 1/13 (7.69%)",
            "  Pneumonia 1/13 (7.69%)",
            "  Urinary tract infection 0/13 (0.00%)",
            "  Lumbar vertebral fracture 0/13 (0.00%)",
            "  Ammonia increased 0/13 (0.00%)",
            "  Hepatic encephalopathy 0/13 (0.00%)"
        ]
    },
    "4243dc45-5a64-486d-ae2a-11448db00dcf": {
        "Section_id": "adverse_events",
        "Statement": "Cohort 1 of the primary trial 15% less total adverse events than cohort 2 of the secondary trial.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 88/291 (30.24%)",
            "  Anemia3/291 (1.03%)",
            "  Febrile Neutropenia11/291 (3.78%)",
            "  Leukopenia1/291 (0.34%)",
            "  Neutropenia7/291 (2.41%)",
            "  Thrombocytopenia2/291 (0.69%)",
            "  Cardiac Arrest1/291 (0.34%)",
            "  Pericardial Effusion1/291 (0.34%)",
            "  Pericarditis1/291 (0.34%)",
            "  Tachycardia2/291 (0.69%)",
            "  Diplopia1/291 (0.34%)",
            "  Macular Hole1/291 (0.34%)",
            "  Abdominal Pain3/291 (1.03%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 30/98 (30.61%)",
            "  NEUTROPENIA 1/98 (1.02%)",
            "  ATRIAL FIBRILLATION 1/98 (1.02%)",
            "  CARDIAC FAILURE 1/98 (1.02%)",
            "  TACHYCARDIA 0/98 (0.00%)",
            "  ACUTE VESTIBULAR SYNDROME 1/98 (1.02%)",
            "  VERTIGO 0/98 (0.00%)",
            "  ABDOMINAL PAIN 0/98 (0.00%)",
            "  COLITIS 0/98 (0.00%)",
            "  DIARRHOEA 2/98 (2.04%)",
            "  FEMORAL HERNIA 0/98 (0.00%)",
            "  HAEMATEMESIS 0/98 (0.00%)",
            "  ILEUS 0/98 (0.00%)",
            "  NAUSEA 0/98 (0.00%)",
            "Adverse Events 2:",
            "  Total: 46/102 (45.10%)",
            "  NEUTROPENIA 0/102 (0.00%)",
            "  ATRIAL FIBRILLATION 0/102 (0.00%)",
            "  CARDIAC FAILURE 0/102 (0.00%)",
            "  TACHYCARDIA 2/102 (1.96%)",
            "  ACUTE VESTIBULAR SYNDROME 0/102 (0.00%)",
            "  VERTIGO 1/102 (0.98%)",
            "  ABDOMINAL PAIN 2/102 (1.96%)",
            "  COLITIS 1/102 (0.98%)",
            "  DIARRHOEA 8/102 (7.84%)",
            "  FEMORAL HERNIA 1/102 (0.98%)",
            "  HAEMATEMESIS 1/102 (0.98%)",
            "  ILEUS 1/102 (0.98%)"
        ]
    },
    "4619b957-3368-47b9-b949-01ec91208f96": {
        "Section_id": "adverse_events",
        "Statement": "the secondary trial recorded more cardiac related adverse events than the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 17/50 (34.00%)",
            "  Fatigue  4/50 (8.00%)",
            "  Papulopustular rash  1/50 (2.00%)",
            "  Alanine aminotransferase increased  5/50 (10.00%)",
            "  Aspartate aminotransferase increased  4/50 (8.00%)",
            "  Alkalosis  1/50 (2.00%)",
            "  Anorexia  1/50 (2.00%)",
            "  Hyperglycemia  2/50 (4.00%)",
            "  Nervous system disorders - Other  1/50 (2.00%)",
            "  Dry skin  1/50 (2.00%)",
            "  Rash acneiform  1/50 (2.00%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 27/94 (28.72%)",
            "  Anaemia 2/94 (2.13%)",
            "  Febrile neutropenia 2/94 (2.13%)",
            "  Leukopenia 1/94 (1.06%)",
            "  Neutropenia 0/94 (0.00%)",
            "  Thrombocytopenia 1/94 (1.06%)",
            "  Arrhythmia 0/94 (0.00%)",
            "  Atrial fibrillation 0/94 (0.00%)",
            "  Cardiac failure congestive 0/94 (0.00%)",
            "  Cardiomyopathy 0/94 (0.00%)",
            "  Pericardial effusion 0/94 (0.00%)",
            "  Tachycardia 0/94 (0.00%)",
            "Adverse Events 2:",
            "  Total: 36/93 (38.71%)",
            "  Anaemia 2/93 (2.15%)",
            "  Febrile neutropenia 9/93 (9.68%)",
            "  Leukopenia 3/93 (3.23%)",
            "  Neutropenia 4/93 (4.30%)",
            "  Thrombocytopenia 1/93 (1.08%)",
            "  Arrhythmia 1/93 (1.08%)",
            "  Atrial fibrillation 1/93 (1.08%)",
            "  Cardiac failure congestive 3/93 (3.23%)",
            "  Cardiomyopathy 2/93 (2.15%)",
            "  Pericardial effusion 1/93 (1.08%)",
            "  Tachycardia 1/93 (1.08%)"
        ]
    },
    "46906361-5133-4db9-b9e5-b9b7f80a8666": {
        "Section_id": "adverse_events",
        "Statement": "the primary trial and the secondary trial recorded the same proportion of patients experiencing nausea.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 9/23 (39.13%)",
            "  Anemia  1/23 (4.35%)",
            "  Diarrhea  1/23 (4.35%)",
            "  Nausea  1/23 (4.35%)",
            "  Fracture  1/23 (4.35%)",
            "  ALT  1/23 (4.35%)",
            "  AST  1/23 (4.35%)",
            "  INR  1/23 (4.35%)",
            "  PTT  1/23 (4.35%)",
            "  Glucose, high  1/23 (4.35%)",
            "  Limb Pain  1/23 (4.35%)",
            "  Ataxia  2/23 (8.70%)",
            "  Neurology - Other  1/23 (4.35%)",
            "  Seizure  1/23 (4.35%)",
            "  Syncope  1/23 (4.35%)",
            "  Confusion  1/23 (4.35%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 14/52 (26.92%)",
            "  Febrile neutropenia * 1/52 (1.92%)",
            "  Tachycardia * 1/52 (1.92%)",
            "  Atrial fibrillation * 0/52 (0.00%)",
            "  Duodenal ulcer * 1/52 (1.92%)",
            "  Gastric ulcer * 1/52 (1.92%)",
            "  Nausea * 1/52 (1.92%)",
            "  Abdominal pain * 0/52 (0.00%)",
            "  Asthenia * 1/52 (1.92%)",
            "  Disease progression * 1/52 (1.92%)",
            "  Mucosal inflammation * 1/52 (1.92%)",
            "  Appendicitis * 1/52 (1.92%)",
            "Adverse Events 2:",
            "  Total: 4/20 (20.00%)",
            "  Febrile neutropenia * 0/20 (0.00%)",
            "  Tachycardia * 0/20 (0.00%)",
            "  Atrial fibrillation * 1/20 (5.00%)",
            "  Duodenal ulcer * 0/20 (0.00%)",
            "  Gastric ulcer * 0/20 (0.00%)",
            "  Nausea * 0/20 (0.00%)",
            "  Abdominal pain * 1/20 (5.00%)",
            "  Asthenia * 0/20 (0.00%)",
            "  Disease progression * 0/20 (0.00%)",
            "  Mucosal inflammation * 0/20 (0.00%)",
            "  Appendicitis * 0/20 (0.00%)"
        ]
    },
    "4a4f3e9e-6a29-4715-8000-2eec90e9bb5d": {
        "Section_id": "results",
        "Statement": "All cohorts in the primary trial had lower number of participants with pCR compared to cohort 1 of the secondary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Outcome Measurement: ",
            "  Complete Pathological Response (pCR) Rate in Breast and Axilla According to the Miller&Payne Criteria (G5-A and G5-D).",
            "  Within 3-4 weeks after last docetaxel dose the surgery was performed to evaluate pathological response. According to the Miller&Payne Criteria, pCR in node-negative patients is a grade 5-A and in node-positive patients is a grade 5-D.",
            "  Time frame: Up to 16 weeks",
            "Results 1: ",
            "  Arm/Group Title: Arm 1: EC -> D + Lapatinib",
            "  Arm/Group Description: EC -> D + Lapatinib",
            "  Drugs plus Biological",
            "  Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -> Docetaxel (D) + lapatinib each 21 days for 4 cycles)",
            "  Overall Number of Participants Analyzed: 51",
            "  Measure Type: Number",
            "  Unit of Measure: percentage of participants with pCR  23.5        (11.9 to 35.1)",
            "Results 2: ",
            "  Arm/Group Title: Arm 2: EC -> D + Trastuzumab",
            "  Arm/Group Description: EC -> D + Trastuzumab",
            "  Drug plus Biological",
            "  Epirubicin + Cyclophosphamide (EC) each 21 days for 4 cycles -> Docetaxel (D) + Trastuzumab each 21 days for 4 cycles",
            "  Overall Number of Participants Analyzed: 48",
            "  Measure Type: Number",
            "  Unit of Measure: percentage of participants with pCR  47.9        (33.8 to 62.0)"
        ],
        "Secondary_CT": [
            "Outcome Measurement: ",
            "  Number of Patients With a Pathological Complete Response (pCR) Who Received Targeted Therapy With Trastuzumab and Pertuzumab or Bevacizumab Predicted by Genomically-derived Molecular Subtypes.",
            "  Number of patients with a pathological complete response (pCR) who received targeted therapy with trastuzumab and pertuzumab or bevacizumab predicted by genomically-derived molecular subtypes (HER2 positive or HER2 negative. pCR is defined as absence of invasive cancer in breast or lymph nodes after neoadjuvant chemotherapy.",
            "  Time frame: Up to 30 days after last cycle of treatment",
            "Results 1: ",
            "  Arm/Group Title: Cohort 1P (HER2 Positive)",
            "  Arm/Group Description: Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats very 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.",
            "  Overall Number of Participants Analyzed: 5",
            "  Measure Type: Count of Participants",
            "  Unit of Measure: Participants  4  80.0%",
            "Results 2: ",
            "  Arm/Group Title: Cohort 1T (HER2 Positive)",
            "  Arm/Group Description: Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.",
            "  Overall Number of Participants Analyzed: 6",
            "  Measure Type: Count of Participants",
            "  Unit of Measure: Participants  6 100.0%"
        ]
    },
    "4ab00376-83a4-467e-8a1e-6b8b1643a8f0": {
        "Section_id": "eligibility",
        "Statement": "Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial",
        "Label": "Entailment",
        "Primary_CT": [
            "Inclusion Criteria:",
            "  Patients must have cytologically/histologically documented locally advanced or metastatic breast cancer with either:",
            "  Progression on treatment with any aromatase inhibitor for metastatic disease;",
            "  Recurrence while on adjuvant aromatase inhibitors or within 12 months of completion;",
            "  Recurrence after having completed adjuvant tamoxifen for at least 12 months;",
            "  Patient who are not candidates for or are intolerant of aromatase inhibitor treatment;",
            "  Patients are allowed (but not required) to have one prior chemotherapy regimen for metastatic disease.",
            "  Tumors must express estrogen or progesterone receptor.",
            "  Patients are eligible regardless of the menopausal status.",
            "  Age > 18 years old",
            "  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.",
            "  Patients must be able to give informed consent and able to follow guidelines given in the study.",
            "  Patients must have acceptable organ function, as defined by the following laboratory parameters: white blood count (WBC) >3.0 x 10^9/L; absolute neutrophil count (ANC) >1.5 x 10^9/L; hemoglobin (Hgb) >10.0g/dL; platelets (PLT) >100 x 10^9/L, Bilirubin < 2.0 mg/dl, aspartate aminotransferase/alanine aminotransferase (AST/ALT) < 2.5 X upper limit of normal (ULN), Creatinine <1.8 mg/dl (Creatinine clearance >60 ml/min).",
            "  Women of childbearing age must have a negative pregnancy test. All patients of reproductive potential must use an effective method of contraception during the study and 6 months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year.",
            "  Patients must have measurable disease by RECIST criteria by staging studies performed within 30 days of enrollment. For patients with bone only disease: For this protocol isolated bone lesions can be classified as target lesions if they are measurable by MRI at screening and must be followed by MRI.",
            "  Both men and women of all races and ethnic groups are eligible for this trial.",
            "Exclusion Criteria:",
            "  Patients must not have received tamoxifen for metastatic disease.",
            "  Patients must not have evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.",
            "  Patients must be disease-free of prior invasive malignancies for > 5 years with the exception of: curatively-treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix.",
            "  Pregnant and breast-feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.",
            "  Patients with uncontrolled central nervous system (CNS) metastasis or a history of seizures are excluded. Patients with stable CNS metastasis (either surgically resected, treated with gamma knife or stable for 3 months following whole brain radiation therapy [WBRT] are eligible). Patients with stable brain metastases will need an MRI within 4 weeks prior to start of therapy.",
            "  Patients may not be receiving any other investigational agents and must have stopped all other histone deacetylase inhibitors (including Valproic acid) or other hormonal therapies.",
            "  Patients must have discontinued their prior therapies for breast cancer and radiation therapy for a minimum of 3 weeks, patient is excluded if radiation therapy was given to a single measurable lesion and the disease is otherwise not measurable.",
            "  Patients are excluded if they have any known hypersensitivity reaction to tamoxifen.",
            "  Patient with a history of blood clots are not eligible.",
            "  Women who have abnormal vaginal bleeding and/or endometrial hyperplasia or cancer are not eligible.",
            "  Patients with evidence of visceral crisis are not eligible for this study."
        ],
        "Secondary_CT": [
            "Inclusion Criteria:",
            "  Ability to understand and the willingness to sign a written informed consent document.",
            "  Signed written informed consent.",
            "  Women undergoing sentinel lymph node biopsy.",
            "  Women with breast cancer with known or suspected lymph node involvement.",
            "  Women undergoing sentinel node identification and completion axillary lymph node dissection.",
            "  Women of 18 years of age or older.",
            "  Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2.",
            "  Complete Blood Count (CBC) and basic Metabolic Panel within 6 months",
            "Exclusion Criteria:",
            "  History of liver or kidney failure will not be eligible.",
            "  Allergies to iodine containing products will not be eligible.",
            "  Women who are pregnant will not be eligible.",
            "  Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements."
        ]
    },
    "5311216c-94e0-4d04-acd2-b95b932ddc02": {
        "Section_id": "adverse_events",
        "Statement": "the primary trial recorded at least one patient with an infection, whereas in the secondary trial none where observed.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 15/122 (12.30%)",
            "  febrile neutropenia 4/122 (3.28%)",
            "  Neutropenia 0/122 (0.00%)",
            "  Angina unstable 1/122 (0.82%)",
            "  Coronary artery disease 1/122 (0.82%)",
            "  Myocardial infarction 1/122 (0.82%)",
            "  Diarrhoea 2/122 (1.64%)",
            "  Colitis 1/122 (0.82%)",
            "  Pyrexia 2/122 (1.64%)",
            "  Chest pain 1/122 (0.82%)",
            "  Pneumonia 1/122 (0.82%)",
            "  Catheter site cellulitis 1/122 (0.82%)",
            "Adverse Events 2:",
            "  Total: 7/34 (20.59%)",
            "  febrile neutropenia 1/34 (2.94%)",
            "  Neutropenia 1/34 (2.94%)",
            "  Angina unstable 0/34 (0.00%)",
            "  Coronary artery disease 0/34 (0.00%)",
            "  Myocardial infarction 0/34 (0.00%)",
            "  Diarrhoea 0/34 (0.00%)",
            "  Colitis 0/34 (0.00%)",
            "  Pyrexia 0/34 (0.00%)",
            "  Chest pain 0/34 (0.00%)",
            "  Pneumonia 1/34 (2.94%)",
            "  Catheter site cellulitis 0/34 (0.00%)",
            "  Infection 1/34 (2.94%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 17/65 (26.15%)",
            "  Febrile neutropenia 3/65 (4.62%)",
            "  Neutropenia 2/65 (3.08%)",
            "  Pancytopenia 1/65 (1.54%)",
            "  Thrombocytopenia 1/65 (1.54%)",
            "  Cardiac arrest 2/65 (3.08%)",
            "  Myocardial infarction 1/65 (1.54%)",
            "  Diarrhoea 5/65 (7.69%)",
            "  Stomatitis 1/65 (1.54%)",
            "  Vomiting 2/65 (3.08%)",
            "  Fatigue 1/65 (1.54%)",
            "  Jaundice 1/65 (1.54%)",
            "  Neutropenic infection 2/65 (3.08%)"
        ]
    },
    "55704a1f-eab2-44ea-a6de-8df508a28066": {
        "Section_id": "eligibility",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "Primary_CT": [
            "DISEASE CHARACTERISTICS:",
            "  Histologically or cytologically confirmed diagnosis of adenocarcinoma of the breast",
            "  Evidence of metastatic involvement (stage IV disease)",
            "  Patients must have measurable disease",
            "  At least one measurable lesion as defined by the Response Evaluation Criteria in Solid Tumors (RECIST)",
            "  Treated brain metastases (surgery or radiation therapy) allowed if clinically stable",
            "  Patients with leptomeningeal disease are ineligible",
            "  Hormone receptor status:",
            "  Not specified",
            "  PATIENT CHARACTERISTICS:",
            "  Eastern Cooperative Oncology Group (ECOG) performance status 0-2",
            "  Male or female",
            "  Menopausal status not specified",
            "  Absolute neutrophil count (ANC)  1,500/mm^3",
            "  Platelet count  100,000/mm^3",
            "  Creatinine clearance > 50 mL/min",
            "  Fertile patients must use effective contraception",
            "  No history of another severe and/or life-threatening medical disease",
            "  No other active primary malignancy",
            "  Not pregnant or nursing",
            "  Negative pregnancy test",
            "  Patients with asymptomatic HIV infection are eligible",
            "  Liver dysfunction score  9",
            "  No pre-existing liver disease (i.e., cirrhosis or active viral hepatitis)",
            "  No active gastrointestinal malabsorption illness",
            "  No clinically significant cardiac disease, including the following:",
            "  Congestive heart failure, symptomatic coronary artery disease, and cardiac arrhythmias not well controlled with medication, or myocardial infarction within the past six months",
            "  No prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenase deficiency",
            "  No history of uncontrolled seizures or central nervous system disorders",
            "  No significant history of noncompliance to medical regimens",
            "  No clinically significant psychiatric disability that would preclude study compliance",
            "  PRIOR CONCURRENT THERAPY:",
            "  No previous capecitabine",
            "  Up to 3 prior cytotoxic regimens allowed for metastatic disease",
            "  Prior noncytotoxic therapy allowed (e.g., hormonal treatment or trastuzumab)",
            "  No other concurrent therapies intended to treat the primary condition including chemotherapy, biologic agents, or immunotherapy",
            "  No concurrent anti-estrogen therapy, radiation therapy, or investigational systemic therapy",
            "  No other concurrent investigational drugs",
            "  No concurrent use of the following drugs: warfarin for full anticoagulation, cimetidine, or azidothymidine (AZT)",
            "  Mini-dose warfarin for prophylaxis of central venous catheter thrombosis allowed",
            "  At least 4 weeks since prior sorivudine or brivudine",
            "  Concurrent use of bisphosphonates allowed if initiated before beginning study therapy",
            "  Concurrent use of megestrol acetate suspension as an appetite stimulant allowed"
        ],
        "Secondary_CT": [
            "DISEASE CHARACTERISTICS:",
            "  Histologically or cytologically confirmed primary adenocarcinoma of the breast",
            "  Locally recurrent or metastatic disease",
            "  Must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab (Herceptin\u00ae) or have previously received trastuzumab in the past",
            "  Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm by conventional techniques or as > 10 mm by spiral CT scan.",
            "  No known CNS disease",
            "  Hormone receptor status not specified",
            "  PATIENT CHARACTERISTICS:",
            "Inclusion criteria:",
            "  Postmenopausal status not specified",
            "  ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%",
            "  Life expectancy > 12 weeks",
            "  WBC  3,000/mcL",
            "  Absolute neutrophil count  1,500/mcL",
            "  Platelet count  100,000/mcL",
            "  Total bilirubin normal",
            "  AST and ALT  2.5 times upper limit of normal (ULN)",
            "  Alkaline phosphatase  2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis)",
            "  Creatinine  1.5 mg/dL",
            "  Not pregnant or nursing",
            "  Negative pregnancy test",
            "  Fertile patients must use effective contraception",
            "  No other concurrent malignancies within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix",
            "Exclusion criteria:",
            "  Pre-existing neuropathy  grade 1",
            "  Uncontrolled intercurrent illness including, but not limited to, any of the following:",
            "  Ongoing or active infection",
            "  Symptomatic congestive heart failure",
            "  Unstable angina pectoris",
            "  Cardiac arrhythmia",
            "  Serious, non-healing wound, ulcer, or bone fracture",
            "  Psychiatric illness/social situations that would limit compliance with study requirements",
            "  Inadequately controlled hypertension (defined as systolic blood pressure > 150 mm Hg and/or diastolic blood pressure > 100 mm Hg on antihypertensive medications)",
            "  History of hypertensive crisis or hypertensive encephalopathy",
            "  New York Heart Association class II-IV congestive heart failure",
            "  History of myocardial infarction or unstable angina within the past 6 months",
            "  History of stroke or transient ischemic attack within the past 6 months",
            "  Significant vascular disease (e.g., aortic aneurysm, aortic dissection)",
            "  Symptomatic peripheral vascular disease",
            "  Evidence of bleeding diathesis or coagulopathy",
            "  Significant traumatic injury within the past 28 days",
            "  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months",
            "  Proteinuria, as demonstrated by either urine protein:creatinine ratio  1.0 OR urine dipstick for proteinuria  2+",
            "  Patients discovered to have  2+ proteinuria on dipstick urinalysis at baseline must demonstrate 24-hour urine protein  1g",
            "  History of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation, paclitaxel, bevacizumab, carboplatin, albumin, drug product excipients, or chemically similar agents",
            "  PRIOR CONCURRENT THERAPY:",
            "  See Disease Characteristics",
            "  Recovered from all prior therapy",
            "  No prior chemotherapy for locally recurrent or metastatic disease",
            "  Prior neoadjuvant or adjuvant chemotherapy allowed",
            "  More than 1 week since prior core biopsy or other minor surgical procedure, excluding placement of a vascular access device",
            "  More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy",
            "  More than 4 weeks since prior radiotherapy",
            "  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)",
            "  At least 1 year since prior taxane regimen",
            "  No other concurrent investigational agents",
            "  Concurrent anticoagulation allowed, provided the following criteria are met:",
            "  Stable dose of warfarin or low molecular weight heparin",
            "  INR within desired range (2-3)",
            "  No evidence of active bleeding or coagulopathy",
            "  No concurrent combination antiretroviral therapy for HIV-positive patients",
            "  No other concurrent radiotherapy, chemotherapy, immunotherapy, or antitumor hormonal therapy"
        ]
    },
    "567ec6e3-87aa-4a4a-94b8-ebdf2e0cbf64": {
        "Section_id": "intervention",
        "Statement": "All Participants in the primary trial and the secondary trial are receiving the same daily dose of oral Letrozole for the same duration of time.",
        "Label": "Entailment",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  Arm A: Triptorelin + Letrozol",
            "  Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles",
            "  Triptorelin: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)",
            "  Letrozole: Letrozole 2.5 mg orally every day for 6 cycles",
            "INTERVENTION 2: ",
            "  Arm B: Degarelix + Letrozol",
            "  Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles",
            "  Degarelix: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)",
            "  Letrozole: Letrozole 2.5 mg orally every day for 6 cycles"
        ],
        "Secondary_CT": [
            "INTERVENTION 1: ",
            "  Zoledronic Acid Upfront",
            "  Participants in the upfront arm received Zoledronic Acid 4 mg i.v. on Day 1 and every 6 months until disease progression (recurrence)or the end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.",
            "  Letrozole : Participants received 2.5 mg daily.",
            "  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months.",
            "INTERVENTION 2: ",
            "  Zoledronic Acid Delayed-start",
            "  In lieu of a placebo arm, which was considered unethical for this trial, a delayed start arm was used. Participants who met certain clinical criteria indicating risk of lumbar spine or total hip fracture, or experienced clinical fracture unrelated to trauma or any asymptomatic fracture discovered at the Month 36 scheduled visit, were started on zoledronic acid 4 mg i.v. and for every 6 months until disease progression (recurrence) or end of study. Participants also received Letrozole 2.5 daily plus calcium (1000-1200 mg) and vitamin D (400-800 IU) daily.",
            "  Letrozole : Participants received 2.5 mg daily.",
            "  Zoledronic Acid : Participants received Zoledronic Acid 4 mg IV 15-minute infusion every 6 months."
        ]
    },
    "57cf3760-1692-439f-bbe2-82a6bc8862ce": {
        "Section_id": "intervention",
        "Statement": "Cohort 2 subjects of the primary trial receive 3.25 mg of vaginal DHEA gel QD more than cohort 1 subjects, of the two cohorts in the secondary trial only cohort 1 recieves Duloxetine 30 mg daily.",
        "Label": "Entailment",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  Arm I Low Dose DHEA",
            "  Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.",
            "INTERVENTION 2: ",
            "  Arm II High Dose DHEA",
            "  Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study."
        ],
        "Secondary_CT": [
            "INTERVENTION 1: ",
            "  Arm 1 (Patients With Pain)",
            "  Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.",
            "  Duloxetine: Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.",
            "INTERVENTION 2: ",
            "  Arm 2 (Patients Without Pain -- Control)",
            "  Patient reported pain and symptoms assessment for comparison at baseline."
        ]
    },
    "5eafb3a1-473a-4270-848d-173e5dca9466": {
        "Section_id": "eligibility",
        "Statement": "Patients with Leukemia, Hepatitis or Cataracts cannot be included in the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Inclusion Criteria:",
            "  Adult women with proven diagnosis of advanced adenocarcinoma of the breast (locoregional recurrent or metastatic disease).",
            "  Women who are not of childbearing potential.",
            "  ER-positive and/or Progesterone receptor (PgR)-positive tumor based on local laboratory results (test as per local practice).",
            "  HER2-negative breast cancer based on local laboratory results (test as per local practice or local guidelines).",
            "  Patients must be appropriate candidates for letrozole therapy.",
            "  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.",
            "  Adequate bone marrow function.",
            "  Adequate liver function",
            "  Adequate renal function.",
            "Exclusion Criteria:",
            "  Known hypersensitivity to letrozole, or any of its excipients, or to any palbociclib excipients.",
            "  Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4 isoenzymes within 7 days prior to study entry.",
            "  Prior treatment with any CDK inhibitor.",
            "  Previous participation in a palbociclib clinical study.",
            "  Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry and/or during study participation.",
            "  QTc >480 msec; history of QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes.",
            "  High cardiovascular risk, including, but not limited to recent myocardial infarction, severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to enrollment.",
            "  Diagnosis of any second invasive malignancy within the last 3 years prior to enrollment. Note: patients with adequately treated basal cell or squamous cell skin cancer, a history of intraepithelial neoplasia or in situ disease (eg, carcinoma in situ of the cervix or melanoma in situ) may enter.",
            "  Active uncontrolled or symptomatic brain metastases. Previously treated and clinically stable, brain metastases are permitted.",
            "  Other severe acute or chronic medical or psychiatric conditions.",
            "  Patients who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees directly involved in the conduct of the study."
        ]
    },
    "633ef768-9e9b-4336-9142-8d4ce7ee2342": {
        "Section_id": "adverse_events",
        "Statement": "There were 10x more patients with Left ventricular systolic dysfunction in the primary trial than in the secondary trial.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 53/218 (24.31%)",
            "  Febrile Neutropenia 2/218 (0.92%)",
            "  Neutropenia 2/218 (0.92%)",
            "  Anaemia 1/218 (0.46%)",
            "  Thrombocytopenia 1/218 (0.46%)",
            "  Pancytopenia 0/218 (0.00%)",
            "  Left Ventricular Dysfunction 4/218 (1.83%)",
            "  Atrial Fibrillation 0/218 (0.00%)",
            "  Angina Unstable 0/218 (0.00%)",
            "  Arteriospasm Coronary 1/218 (0.46%)",
            "  Cardiac Arrest 1/218 (0.46%)",
            "Adverse Events 2:",
            "  Total: 58/228 (25.44%)",
            "  Febrile Neutropenia 1/228 (0.44%)",
            "  Neutropenia 1/228 (0.44%)",
            "  Anaemia 0/228 (0.00%)",
            "  Thrombocytopenia 1/228 (0.44%)",
            "  Pancytopenia 1/228 (0.44%)",
            "  Left Ventricular Dysfunction 13/228 (5.70%)",
            "  Atrial Fibrillation 2/228 (0.88%)",
            "  Angina Unstable 1/228 (0.44%)",
            "  Arteriospasm Coronary 0/228 (0.00%)",
            "  Cardiac Arrest 0/228 (0.00%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 21/82 (25.61%)",
            "  Neutrophils count decreased 1/82 (1.22%)",
            "  Cardiac ischemia/infarction 1/82 (1.22%)",
            "  Left ventricular systolic dysfunction 1/82 (1.22%)",
            "  Hypertension 1/82 (1.22%)",
            "  Supraventricular and nodal arrhythmia 1/82 (1.22%)",
            "  Anorexia 1/82 (1.22%)",
            "  Gastrointestinal perforation 1/82 (1.22%)",
            "  Vomiting 1/82 (1.22%)",
            "  Dehydration 1/82 (1.22%)",
            "  Diarrhoea 1/82 (1.22%)"
        ]
    },
    "67522762-9423-4e3d-bf75-247f84ba7f05": {
        "Section_id": "eligibility",
        "Statement": " To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase  < 2.5 x ULN, aspartate aminotransferase  <= 1.5 x ULN and Hemoglobin > 10 g/dL.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Inclusion Criteria:",
            "  Patients must be female.",
            "  The patient must be greater than/equal to 18 years old",
            "  The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy.",
            "  Patients must have clinical Stage IIIA, IIIB, or IIIC disease (American Joint Committee on Cancer [AJCC] staging criteria) with a primary breast tumor that is greater than/equal to 2.0 cm measured by clinical exam, unless the patient has inflammatory breast carcinoma, in which case measurable disease is not required.",
            "  Patients must have the ability to swallow oral medication.",
            "  The patient's Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1.",
            "  At the time of study entry, blood counts must meet the following criteria:",
            "  Absolute neutrophil count (ANC) must be greater than/equal to 1200/mm3.",
            "  Platelet count must be greater than/equal to 100,000/mm^3.",
            "  Hemoglobin must be greater than/equal to 10 g/dL.",
            "  The following criteria for evidence of adequate hepatic function must be met:",
            "  total bilirubin must be less than/equal to upper limit of normal (ULN) for the lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN) due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and",
            "  alkaline phosphatase must be less than 2.5 x ULN for the lab; and",
            "  aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab.",
            "  Alkaline phosphatase and AST may not both be greater than the ULN. For example, if the alkaline phosphatase is greater than the ULN but less than/equal to 2.5 x ULN, then the AST must be less than/equal to the ULN. If the AST is greater than the ULN but less than/equal to 1.5 x ULN, then the alkaline phosphatase must be less than/equal to ULN.",
            "  Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan or positron emission tomography (PET) scan does not demonstrate metastatic disease. Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy.",
            "  Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], MRI, or PET scan) does not demonstrate metastatic disease and adequate hepatic function.",
            "  The following criteria for evidence of adequate renal function must be met:",
            "  Serum creatinine less than/equal to ULN for the lab.",
            "  Calculated creatinine clearance must be greater than 50 mL/min.",
            "  Urine protein/creatinine (UPC) ratio must be less than 1.0.",
            "  Patients must have their left ventricular ejection fraction (LVEF) assessed by multigated acquisition (MUGA) scan or echocardiogram within 3 months prior to study entry. The LVEF must be greater than/equal to the lower limit of normal (LLN) for the cardiac imaging facility performing the MUGA scan or echocardiogram. Note: If the cardiac imaging facility cannot provide a LLN, use 50% as the LLN value.",
            "  Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments to determine if bevacizumab therapy can be continued following doxorubicin and cyclophosphamide (AC) and postoperatively, it is critical that this baseline study be an accurate assessment of the patient's LVEF. If the baseline LVEF is greater than 65%, the MUGA scan or echocardiogram must be repeated prior to study entry. The lower of the two LVEF values should be used as the baseline LVEF.",
            "  Patients must have an electrocardiogram (EKG) within 3 months prior to study entry.",
            "Exclusion Criteria:",
            "  Tumor determined to be strongly HER2-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization (positive for gene amplification).",
            "  Excisional biopsy for this primary tumor.",
            "  Synchronous bilateral invasive breast cancer.",
            "  Surgical axillary staging procedure prior to study entry (Exceptions: 1) fine needle aspiration (FNA) of an axillary node is permitted for any patient, and 2) although not recommended, a sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted.)",
            "  History of any of the following cancers:",
            "  Ipsilateral breast cancer: invasive, ductal carcinoma in situ (DCIS) treated with any therapy other than excision",
            "  Contralateral breast cancer: invasive within the past 5 years (Patients with history of DCIS or synchronous DCIS are eligible)",
            "  History of non-breast malignancies within the 5 years prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the previous 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.",
            "  Prior therapy with anthracyclines, taxanes, capecitabine, or bevacizumab for any malignancy.",
            "  Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to study entry. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before study entry. In such a case, hormonal therapy must stop at or before study entry and be re-started, if indicated, following chemotherapy.",
            "  Any of the following cardiac conditions:",
            "  angina pectoris that requires the use of anti-anginal medication;",
            "  history of documented congestive heart failure;",
            "  serious cardiac arrhythmia requiring medication;",
            "  severe conduction abnormality;",
            "  valvular disease with documented cardiac function compromise; or",
            "  uncontrolled hypertension defined as blood pressure greater than 150/90 on antihypertensive therapy. (Patients with hypertension that is well controlled on medication are eligible.)",
            "  History of myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function.",
            "  History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).",
            "  History of other arterial thrombotic event within 12 months before study entry.",
            "  Symptomatic peripheral vascular disease.",
            "  Any significant bleeding within 6 months before study entry.",
            "  Serious or non-healing wound, skin ulcers, or bone fracture.",
            "  Gastroduodenal ulcer(s) determined by endoscopy to be active.",
            "  Invasive procedures defined as follows:",
            "  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy. (Note: Placement of a vascular access device is not considered a major surgical procedure.)",
            "  Anticipation of need for major surgical procedures (other than the required breast surgery) during the course of the study.",
            "  Known bleeding diathesis or coagulopathy. (Patients on warfarin with an in-range international normalized ratio [INR] [usually between 2 and 3] are eligible.)",
            "  Other nonmalignant systemic disease (cardiovascular, renal, hepatic, diabetes, etc.) that would preclude the patient from receiving study treatment or would prevent required follow-up.",
            "  Sensory/motor neuropathy greater than/equal to grade 2, as defined by the NCI's Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0).",
            "  Conditions that would prohibit administration of corticosteroids.",
            "  History of hypersensitivity reaction to drugs formulated with polysorbate 80.",
            "  Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention. Patients are eligible only if these medications are discontinued prior to study entry.",
            "  Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. These patients are eligible if this therapy is discontinued prior to study entry. (Women of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy and for at least 3 months after completion of bevacizumab.)",
            "  Pregnancy or lactation at the time of study entry.",
            "  Use of any investigational agent within 4 weeks prior to enrollment in the study.",
            "  Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements."
        ],
        "Secondary_CT": [
            "Inclusion Criteria:",
            "  Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group",
            "  Premenopausal",
            "  More than 6 months since initiating or discontinuing oral contraceptives",
            "  At increased risk for breast cancer, as indicated by >= 1 of the following risk factors:",
            "  BRCA1/2 mutation characterized as deleterious or of uncertain significance",
            "  Prior atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ",
            "  Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia",
            "  Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria:",
            "  >= 4 relatives with breast cancer",
            "  >= 2 relatives diagnosed with breast cancer at  50 years of age",
            "  Breast and ovarian cancer diagnosed in same relative",
            "  No suspicion for breast cancer on baseline mammogram performed between days 1-10 of menstrual cycle within 3 months prior to screening baseline RPFNA",
            "  Exhibits hyperplasia with or without atypia (Masood score >= 14) with >= 500 cells AND Ki-67 positivity >= 2% by RPFNA performed within 6 months prior to initiation of study drug",
            "  Estimated visual mammographic breast density category >= 5% on mammogram performed within 6 months prior to initiation of study drug",
            "  Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen oral contraceptives or a contraceptive device (e.g., Mirena IUD) Values for metabolic profile and blood count within normal limits",
            "  Absolute granulocyte count > 1,000/mm^3",
            "  Platelets > 100,000/mm^3",
            "  Hemoglobin > 10 g/dL",
            "  Bilirubin < 2.0 mg/dL",
            "  AST < 2 times upper limit of normal (ULN)",
            "  Albumin > 3.0 g/dL",
            "  Creatinine < 1.5 mg/dL",
            "  Alkaline phosphatase < 2 times ULN",
            "  Concurrent hormonal contraceptives allowed provided patient remains on the same hormonal regimen from 3 months prior to baseline aspiration until the completion of study treatment",
            "  Fertile patients must use effective contraception during and for 3 months after completion of study treatment",
            "  Willing to ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily)",
            "  Negative pregnancy test prior to receiving study agent",
            "  Exclusion Criteria",
            "  pregnant or nursing",
            "  nursing within the past 6 months",
            "  Known osteoporosis or severe osteopenia (T-score -2 or worse by DEXA)",
            "  History of symptomatic endometriosis with pelvic pain, poorly controlled migraines, or hot flashes",
            "  History of deep venous thrombosis",
            "  History of allergic reactions attributed to compounds of similar chemical or biological composition to the study agent",
            "  Other condition or concurrent illness that, in the opinion of the investigator, would make the patient a poor candidate for RPFNA",
            "  Less than 1 year since prior use of aromatase inhibitors (e.g., anastrozole, exemestane, or letrozole) or selective estrogen receptor modulators (e.g., tamoxifen citrate, raloxifene, or arzoxifene hydrochloride)",
            "  Other concurrent chemopreventive agents",
            "  Concurrent anticoagulants",
            "  Other concurrent investigational agents",
            "  Bilateral breast implants"
        ]
    },
    "6c57e451-a706-4b32-ae71-254e9d0e04de": {
        "Section_id": "adverse_events",
        "Statement": "None of the patients in the primary trial had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 55/238 (23.11%)",
            "  Febrile neutropenia * 5/238 (2.10%)",
            "  Neutropenia * 6/238 (2.52%)",
            "  Leukopenia * 1/238 (0.42%)",
            "  Thrombocytopenia * 0/238 (0.00%)",
            "  Anaemia * 1/238 (0.42%)",
            "  Pancytopenia * 0/238 (0.00%)",
            "  Cardiac failure * 1/238 (0.42%)",
            "  Acute coronary syndrome * 0/238 (0.00%)",
            "  Atrial fibrillation * 0/238 (0.00%)",
            "  Cardiac failure congestive * 0/238 (0.00%)",
            "Adverse Events 2:",
            "  Total: 89/245 (36.33%)",
            "  Febrile neutropenia * 12/245 (4.90%)",
            "  Neutropenia * 10/245 (4.08%)",
            "  Leukopenia * 2/245 (0.82%)",
            "  Thrombocytopenia * 5/245 (2.04%)",
            "  Anaemia * 1/245 (0.41%)",
            "  Pancytopenia * 1/245 (0.41%)",
            "  Cardiac failure * 2/245 (0.82%)",
            "  Acute coronary syndrome * 1/245 (0.41%)",
            "  Atrial fibrillation * 1/245 (0.41%)",
            "  Cardiac failure congestive * 2/245 (0.82%)"
        ]
    },
    "6dea5ffa-066d-45bf-b7e5-df3ae5bca0b6": {
        "Section_id": "adverse_events",
        "Statement": "the secondary trial records several gastrointestinal adverse events, whereas the primary trial doesn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t record any GI adverse events.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 7/52 (13.46%)",
            "  Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 0/52 (0.00%)",
            "  Atrial Fibrillation * 1/52 (1.92%)",
            "  Sepsis * 1/52 (1.92%)",
            "  Muscle weakness upper limb * 1/52 (1.92%)",
            "  Dizziness * 1/52 (1.92%)",
            "  Seizure * 1/52 (1.92%)",
            "  Nervous system disorders - Other, specify *  [1]1/52 (1.92%)",
            "Adverse Events 2:",
            "  Total: 1/30 (3.33%)",
            "  Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe * 1/30 (3.33%)",
            "  Atrial Fibrillation * 0/30 (0.00%)",
            "  Sepsis * 0/30 (0.00%)",
            "  Muscle weakness upper limb * 0/30 (0.00%)",
            "  Dizziness * 0/30 (0.00%)",
            "  Seizure * 0/30 (0.00%)",
            "  Nervous system disorders - Other, specify *  [1]0/30 (0.00%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 16/76 (21.05%)",
            "  Hemoglobin  0/76 (0.00%)",
            "  Left ventricular systolic function  1/76 (1.32%)",
            "  Hypertension  0/76 (0.00%)",
            "  Dehydration  1/76 (1.32%)",
            "  Diarrhea  1/76 (1.32%)",
            "  Hemorrhage, GI - stomach  0/76 (0.00%)",
            "  Perforation, GI - colon  1/76 (1.32%)",
            "  Ulcer, GI - stomach  0/76 (0.00%)",
            "  Pain- head/headache  3/76 (3.95%)",
            "  Pain- back  2/76 (2.63%)",
            "Adverse Events 2:",
            "  Total: 5/29 (17.24%)",
            "  Hemoglobin  1/29 (3.45%)",
            "  Left ventricular systolic function  0/29 (0.00%)",
            "  Hypertension  1/29 (3.45%)",
            "  Dehydration  1/29 (3.45%)",
            "  Diarrhea  0/29 (0.00%)",
            "  Hemorrhage, GI - stomach  1/29 (3.45%)",
            "  Perforation, GI - colon  0/29 (0.00%)",
            "  Ulcer, GI - stomach  1/29 (3.45%)",
            "  Pain- head/headache  0/29 (0.00%)",
            "  Pain- back  0/29 (0.00%)"
        ]
    },
    "77982c81-d147-48d9-909c-18b9a98224e9": {
        "Section_id": "adverse_events",
        "Statement": "Only 1 type of infection recorded across the duration of both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 5/32 (15.63%)",
            "  Leukopenia 1/32 (3.13%)",
            "  Neutropenia 1/32 (3.13%)",
            "  Cataract 1/32 (3.13%)",
            "  Infection 1/32 (3.13%)",
            "  Upper respiratory tract infection 1/32 (3.13%)",
            "  Completed suicide 1/32 (3.13%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 4/6 (66.67%)",
            "  Anemia  0/6 (0.00%)",
            "  Takotsubo cardiomyopathy  1/6 (16.67%)",
            "  Pericardial effusion  0/6 (0.00%)",
            "  Vertigo  1/6 (16.67%)",
            "  Retinal vein occlusion  0/6 (0.00%)",
            "  Gastroenteritis  1/6 (16.67%)",
            "  Vomiting  1/6 (16.67%)",
            "  Diarrhea  0/6 (0.00%)",
            "  Death  2/6 (33.33%)",
            "  Bile duct dilatation  0/6 (0.00%)",
            "  Hepatic hemorrhage  0/6 (0.00%)",
            "Adverse Events 2:",
            "  Total: 25/52 (48.08%)",
            "  Anemia  1/52 (1.92%)",
            "  Takotsubo cardiomyopathy  0/52 (0.00%)",
            "  Pericardial effusion  2/52 (3.85%)",
            "  Vertigo  0/52 (0.00%)",
            "  Retinal vein occlusion  1/52 (1.92%)",
            "  Gastroenteritis  0/52 (0.00%)",
            "  Vomiting  0/52 (0.00%)",
            "  Diarrhea  1/52 (1.92%)",
            "  Death  9/52 (17.31%)",
            "  Bile duct dilatation  1/52 (1.92%)",
            "  Hepatic hemorrhage  1/52 (1.92%)"
        ]
    },
    "80a5cdbc-0721-41b6-af1a-28e3f46557ce": {
        "Section_id": "adverse_events",
        "Statement": "1 patient in the primary trial had a cardiac related adverse event.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 146/573 (25.48%)",
            "  Anaemia 4/573 (0.70%)",
            "  Disseminated intravascular coagulation 0/573 (0.00%)",
            "  Neutropenia 1/573 (0.17%)",
            "  Thrombocytopenia 0/573 (0.00%)",
            "  Acute coronary syndrome 1/573 (0.17%)",
            "  Angina pectoris 1/573 (0.17%)",
            "  Atrial fibrillation 2/573 (0.35%)",
            "  Atrial flutter 0/573 (0.00%)",
            "  Cardiac arrest 1/573 (0.17%)",
            "  Cardiac failure 0/573 (0.00%)",
            "Adverse Events 2:",
            "  Total: 101/570 (17.72%)",
            "  Anaemia 3/570 (0.53%)",
            "  Disseminated intravascular coagulation 1/570 (0.18%)",
            "  Neutropenia 1/570 (0.18%)",
            "  Thrombocytopenia 1/570 (0.18%)",
            "  Acute coronary syndrome 0/570 (0.00%)",
            "  Angina pectoris 1/570 (0.18%)",
            "  Atrial fibrillation 0/570 (0.00%)",
            "  Atrial flutter 1/570 (0.18%)",
            "  Cardiac arrest 0/570 (0.00%)",
            "  Cardiac failure 1/570 (0.18%)"
        ]
    },
    "83b83400-1439-462d-bba3-42817b5b1fa1": {
        "Section_id": "adverse_events",
        "Statement": "Most of the cases of CHF in the primary trial, were in cohort 1.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 12/32 (37.50%)",
            "  Anaemia 0/32 (0.00%)",
            "  Neutropenia 1/32 (3.13%)",
            "  Thrombocytopenia 4/32 (12.50%)",
            "  Atrial fibrillation 1/32 (3.13%)",
            "  Cardiac failure congestive 1/32 (3.13%)",
            "  Myocardial ischaemia 1/32 (3.13%)",
            "  Abdominal discomfort 0/32 (0.00%)",
            "  Ascites 1/32 (3.13%)",
            "  Constipation 0/32 (0.00%)",
            "  Rectal haemorrhage 1/32 (3.13%)",
            "  Vomiting 1/32 (3.13%)",
            "  Fatigue 1/32 (3.13%)",
            "Adverse Events 2:",
            "  Total: 8/20 (40.00%)",
            "  Anaemia 1/20 (5.00%)",
            "  Neutropenia 0/20 (0.00%)",
            "  Thrombocytopenia 1/20 (5.00%)",
            "  Atrial fibrillation 0/20 (0.00%)",
            "  Cardiac failure congestive 0/20 (0.00%)",
            "  Myocardial ischaemia 0/20 (0.00%)",
            "  Abdominal discomfort 1/20 (5.00%)",
            "  Ascites 0/20 (0.00%)",
            "  Constipation 2/20 (10.00%)",
            "  Rectal haemorrhage 0/20 (0.00%)",
            "  Vomiting 0/20 (0.00%)",
            "  Fatigue 0/20 (0.00%)"
        ]
    },
    "883bec6a-bce2-4e60-9304-49a056e66df7": {
        "Section_id": "eligibility",
        "Statement": "A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/\u00ac\u00a8\u00ac\u00b5l and total bilirubin < 1.2 x ULN are eligilbe for the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Inclusion Criteria:",
            "  Age > 18 years",
            "  Women with prior histologically documented diagnosis of breast cancer",
            "  Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and, if ER/PgR +ve, have failed on at least adjuvant hormonal therapy",
            "  Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects",
            "  Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy",
            "  Subjects who have at least one measurable lesion by CT (Computed Tomography) scan or MRI (Magnetic Resonance Imaging) according to modified WHO Tumour Response Criteria",
            "  Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2",
            "  Adequate bone marrow, liver and renal function as assessed by the following laboratory evaluations:",
            "  Hemoglobin > 9.0 g/dl",
            "  Absolute neutrophil count (ANC) > 1,500/mm3",
            "  Platelet count = 100,000/\u00b5l",
            "  Total bilirubin =1.5 x the upper limit of normal.",
            "  Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5 x upper limit of normal (=5 x upper limit of normal for subjects with liver involvement of their cancer)",
            "  Amylase and lipase = 1.5 x the upper limit of normal",
            "  Serum creatinine = 3.0 x the upper limit of normal",
            "  Prothrombin Time (PT) or International Normalized Ratio (INR) and Partial Thromboplastin Time (PTT) < 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists)",
            "  Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice",
            "  Life expectancy of at least 12 weeks",
            "  Signed informed consent must be obtained prior to any study specific procedures",
            "Exclusion Criteria:",
            "  Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumours [Ta, Tis and T1] or other malignancies curatively treated > 2 years prior to entry)",
            "  Congestive heart failure > New York Heart Association (NYHA) Class II",
            "  Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin)",
            "  Active coronary artery disease or ischaemia",
            "  Active clinically serious bacterial or fungal infections (> grade 2 National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3)",
            "  Known History of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C",
            "  Metastatic brain or meningeal tumors unless the subject is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study)",
            "  Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics)",
            "  History of organ allograft",
            "  Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results",
            "  Known or suspected allergy to the investigational agent",
            "  Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.",
            "  Excluded therapies include:",
            "  Anti-cancer chemotherapy, hormonal therapy or immunotherapy during the study or within 4 weeks of study entry. Mytomicin or nitroureas should not be given within 6 weeks of study entry",
            "  Significant surgery within 4 weeks prior to the start of study drug",
            "  Any bone marrow transplant or stem cell rescue within 4 months of the start of study drug",
            "  Radiotherapy during the study or within 3 weeks of the start of drug",
            "  Use of biologic response modifiers, such as Granulocyte-Colony Stimulating Factor (G-CSF), within 3 weeks of study entry",
            "  Investigational drug therapy outside of this trial during or within 30 days prior to start of the study drug",
            "  Concomitant treatment with ketoconazole, itraconazole, ritonavir, or use of grapefruit juice",
            "  Prior use of Raf-Kinase Inhibitors (RKI), Methyl Ethyl Ketone (MEK) or farnesyl transferase inhibitors",
            "  Concomitant treatment or use of St. John's Wort",
            "  Prior use of bevacizumab and all other drugs that target Vascular Endothelial Growth Factor (VEGF)/VEGF receptors"
        ]
    },
    "89fdf182-7474-4e70-baf7-03c8920c4ff3": {
        "Section_id": "intervention",
        "Statement": "Placebo treatment is used in cohort 2 of the secondary trial, but there is only a test group in the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  Arm I (Omega-3-fatty Acid)",
            "  Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity",
            "INTERVENTION 2: ",
            "  Arm II (Placebo)",
            "  Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity"
        ],
        "Secondary_CT": [
            "INTERVENTION 1: ",
            "  Accelerated Partial Breast Brachytherapy",
            "  Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.",
            "  Patients will receive 3400 cGy delivered in 10 twice-daily fractions. Treatment is to be given over 5-7 days with a minimum of 6 hours separation between fractions."
        ]
    },
    "90203158-6477-4486-b8d9-09dcaca63617": {
        "Section_id": "adverse_events",
        "Statement": "There is one case of Cardiopulmonary failure in cohort 1 of the secondary trial, but none in cohort 1 of the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 5/33 (15.15%)",
            "  Left Ventricular Thrombus * 1/33 (3.03%)",
            "  Nausea * 1/33 (3.03%)",
            "  Acute Cholecystitis * 1/33 (3.03%)",
            "  Renal Failure * 1/33 (3.03%)",
            "  Pneumonia * 1/33 (3.03%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 14/76 (18.42%)",
            "  Neutropenia 10/76 (13.16%)",
            "  Febrile neutropenia 1/76 (1.32%)",
            "  Anaemia 0/76 (0.00%)",
            "  Thrombocytopenia 0/76 (0.00%)",
            "  Cardiopulmonary failure 0/76 (0.00%)",
            "  Optic ischaemic neuropathy 0/76 (0.00%)",
            "  Bowel peristalsis increased 1/76 (1.32%)",
            "  Colitis 0/76 (0.00%)",
            "  Diarrhoea 0/76 (0.00%)",
            "  Gastritis 0/76 (0.00%)",
            "  Nausea 0/76 (0.00%)",
            "Adverse Events 2:",
            "  Total: 12/76 (15.79%)",
            "  Neutropenia 2/76 (2.63%)",
            "  Febrile neutropenia 1/76 (1.32%)",
            "  Anaemia 0/76 (0.00%)",
            "  Thrombocytopenia 0/76 (0.00%)",
            "  Cardiopulmonary failure 1/76 (1.32%)",
            "  Optic ischaemic neuropathy 1/76 (1.32%)",
            "  Bowel peristalsis increased 0/76 (0.00%)",
            "  Colitis 1/76 (1.32%)",
            "  Diarrhoea 0/76 (0.00%)",
            "  Gastritis 0/76 (0.00%)",
            "  Nausea 1/76 (1.32%)"
        ]
    },
    "92da8d30-a7e9-4fb4-95e4-484b53279ad7": {
        "Section_id": "results",
        "Statement": "the primary trial and the secondary trial monitor the DFS of their patient cohorts, however the secondary trial reports the % of patients with DFS >= 5 years whereas the primary trial reports % of participants with DFS >= 2 years.",
        "Label": "Entailment",
        "Primary_CT": [
            "Outcome Measurement: ",
            "  Disease-free Survival (DFS)",
            "  Disease-free survival (DFS) for all patients regardless of randomization will be determined by patients' own physicians at the individual study sites during routine follow-up screening. This will occur every three months for the first 24 months after completion of primary therapies and every six months thereafter with clinical exam, and laboratory and radiographic surveillance. The primary objective of the study is disease-free survival (DFS) at 24 months.",
            "  Time frame: Disease-free survival at 24 months",
            "Results 1: ",
            "  Arm/Group Title: Herceptin + NeuVax Vaccine",
            "  Arm/Group Description: Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion, but may be delayed to the fourth or fifth Herceptin infusion with prior approval from the PI. After completion of primary vaccine series, patients will receive NeuVax vaccine booster inoculations to be administered every 6 months x 4 for total treatment duration of 30 months.",
            "  Overall Number of Participants Analyzed: 136",
            "  Measure Type: Number",
            "  Unit of Measure: Percentage of participants who survived  89.8",
            "Results 2: ",
            "  Arm/Group Title: Herceptin + GM-CSF Only",
            "  Arm/Group Description: Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive inoculations of GM-CSF only (250mcg) administered intradermally every 3 weeks for 6 total inoculations, 30-120 minutes after completion of Herceptin infusion. The GM-CSF only inoculation series will begin immediately after completion of the third Herceptin infusion. After completion of six-inoculation primary vaccine series, patients will then receive a total of four GM-CSF only booster inoculations to be administered at 12, 18, 24, and 30 months from the date of the first Herceptin infusion.",
            "  Overall Number of Participants Analyzed: 139",
            "  Measure Type: Number",
            "  Unit of Measure: Percentage of participants who survived  83.8"
        ],
        "Secondary_CT": [
            "Outcome Measurement: ",
            "  Percentage of Participants With Disease Free Survival at 5 Years",
            "  Disease Free Survival was defined as the interval from the date of randomization to the date of local, regional or metastatic relapse or the date of second primary cancer (with the exception of curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix) or death from any cause whichever occured first. Disease free survival was estimated using the Kaplan-Meier method.",
            "  Time frame: From randomization until relapse or death or up to 5 years",
            "Results 1: ",
            "  Arm/Group Title: Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC\u2192T)",
            "  Arm/Group Description: Doxorubicin 60 mg/m  IV bolus injection in combination with cyclophosphamide 600 mg/m  IV bolus injection on Day 1 of every 3 weeks for 4 cycles followed by docetaxel 100 mg/m  IV infusion every 3 weeks for another 4 cycles.",
            "  Overall Number of Participants Analyzed: 1073",
            "  Measure Type: Number",
            "  Unit of Measure: percentage of participants  75.5        (72.8 to 78.2)",
            "Results 2: ",
            "  Arm/Group Title: AC Followed by Docetaxel + Herceptin (AC\u2192TH)",
            "  Arm/Group Description: Doxorubicin 60 mg/m  IV bolus injection in combination with cyclophosphamide 600 mg/m  IV bolus Injection on Day 1 of every 3 weeks for 4 cycles. Herceptin 4 mg/kg IV infusion on Day 1 of Cycle 5, followed by Herceptin 2 mg/kg by IV infusion weekly starting from Day 8; and docetaxel 100 mg/m  IV infusion on Day 2 of Cycle 5, then on Day 1 of every 3 weeks for all subsequent cycles ( total 4 cycles). After completion of the last cycle of chemotherapy, Herceptin 6 mg/kg IV infusion was administered every 3 weeks until 1 year from date of initial Herceptin dose.",
            "  Overall Number of Participants Analyzed: 1074",
            "  Measure Type: Number",
            "  Unit of Measure: percentage of participants  83.2        (80.9 to 85.4)"
        ]
    },
    "93a8e018-ac25-48b2-81d2-fd5b01be8f37": {
        "Section_id": "adverse_events",
        "Statement": "A higher number of patients in the secondary trial suffured from infection compared to those in the primary trial.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 1/41 (2.44%)",
            "  Infection  1/41 (2.44%)",
            "  Creatinine  1/41 (2.44%)",
            "  Hypokalemia  1/41 (2.44%)",
            "  Bicarbonate  1/41 (2.44%)",
            "  SGOT  1/41 (2.44%)",
            "  Alkaline Phosphatase value  1/41 (2.44%)",
            "  Hyperbilirubineamia  1/41 (2.44%)",
            "  Hypoalbuminemia  1/41 (2.44%)",
            "  Leukocytes  1/41 (2.44%)",
            "  Hemoglobin  1/41 (2.44%)",
            "  Neutrophils  1/41 (2.44%)",
            "  INR  1/41 (2.44%)",
            "  PTT  1/41 (2.44%)",
            "Adverse Events 2:",
            "   "
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 14/81 (17.28%)",
            "  Neutropenia1/81 (1.23%)",
            "  Cataract1/81 (1.23%)",
            "  Ascites1/81 (1.23%)",
            "  Gastritis Hemorrhagic1/81 (1.23%)",
            "  Nausea1/81 (1.23%)",
            "  Stomatitis2/81 (2.47%)",
            "  Malaise1/81 (1.23%)",
            "  Oedema1/81 (1.23%)",
            "  Pain1/81 (1.23%)",
            "  Pyrexia1/81 (1.23%)",
            "  Infection2/81 (2.47%)",
            "  Upper Limb Fracture1/81 (1.23%)",
            "  Dehydration1/81 (1.23%)",
            "  Hypercalcemia1/81 (1.23%)"
        ]
    },
    "949ac54b-a871-4134-a507-c98a4de55720": {
        "Section_id": "adverse_events",
        "Statement": "the primary trial recorded cases of Anaphylaxis and Spinal compression fracture, neither of these were observed in the secondary trial.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 13/50 (26.00%)",
            "  Febrile neutropenia 3/50 (6.00%)",
            "  Neutropenia 1/50 (2.00%)",
            "  Pancreatitis 1/50 (2.00%)",
            "  Cholangitis 1/50 (2.00%)",
            "  Cholelithiasis 1/50 (2.00%)",
            "  Anaphylactic reaction  [1]1/50 (2.00%)",
            "  Pneumonia 1/50 (2.00%)",
            "  Pneumonitis chemical 1/50 (2.00%)",
            "  Spinal compression fracture 1/50 (2.00%)",
            "  Dehydration 1/50 (2.00%)",
            "  Electrolyte imbalance 1/50 (2.00%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 1/3 (33.33%)",
            "  FEBRILE NEUTROPENIA 0/3 (0.00%)",
            "  LYMPH NODE PAIN 0/3 (0.00%)",
            "  NEUTROPHIL COUNT DECREASED 0/3 (0.00%)",
            "  THROMBOCYTOPENIA 0/3 (0.00%)",
            "  CHEST PAIN 0/3 (0.00%)",
            "  DEHYDRATION 0/3 (0.00%)",
            "  PLEURAL EFFUSION 1/3 (33.33%)",
            "  PNEUMONITIS 0/3 (0.00%)",
            "  PULMONARY INFILTERATES 0/3 (0.00%)",
            "  ALOPECIA 0/3 (0.00%)"
        ]
    },
    "9ad3444c-143d-4c28-a08a-e0c9cda44900": {
        "Section_id": "adverse_events",
        "Statement": "the primary trial and the secondary trial did not observe any of the same adverse events in their patients.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 25/60 (41.67%)",
            "  Anaemia * 1/60 (1.67%)",
            "  Febrile neutropenia * 2/60 (3.33%)",
            "  Idiopathic thrombocytopenic purpura * 1/60 (1.67%)",
            "  Thrombocytopenia * 3/60 (5.00%)",
            "  Cardiac failure * 1/60 (1.67%)",
            "  Cardiac failure acute * 1/60 (1.67%)",
            "  Cardiogenic shock * 1/60 (1.67%)",
            "  Left ventricular dysfunction * 1/60 (1.67%)",
            "  Anal fistula * 1/60 (1.67%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 4/26 (15.38%)",
            "  Febrile neutropenia * 1/26 (3.85%)",
            "  Gastric volvulus * 20/26 (0.00%)",
            "  General Malaise * 21/26 (3.85%)",
            "  Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%)",
            "  Acute renal failure * 21/26 (3.85%)",
            "Adverse Events 2:",
            "  Total: 1/28 (3.57%)",
            "  Febrile neutropenia * 0/28 (0.00%)",
            "  Gastric volvulus * 21/28 (3.57%)",
            "  General Malaise * 20/28 (0.00%)",
            "  Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)",
            "  Acute renal failure * 20/28 (0.00%)"
        ]
    },
    "9aea5a84-bced-4441-b8b8-154c307f5a03": {
        "Section_id": "results",
        "Statement": "The placebo group in the primary trial had a much lower Median PFS than the MM-121 cohort.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Outcome Measurement: ",
            "  Progression Free Survival (PFS)",
            "  To determine whether MM-121 + exemestane was more effective than placebo + exemestane in prolonging progression-free survival. PFS was a time to event measure, and progression of disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), \"as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions\". Progression free survival was defined as the number of months from the date of randomization to the date of death or progression. If neither death nor progression was observed during the study, PFS data was censored at the last non-progressive disease valid tumor assessment unless the patient was discontinued due to symptomatic deterioration. If this occurred, the patient was counted as having progressive disease (PD).",
            "  Time frame: Time from first dose to date of progression, the longest time frame of 79.1 weeks",
            "Results 1: ",
            "  Arm/Group Title: MM-121 + Exemestane",
            "  Arm/Group Description: MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week, plus exemestane (25 mg) administered orally once per day",
            "  Overall Number of Participants Analyzed: 56",
            "  Median (95% Confidence Interval)",
            "  Unit of Measure: weeks  15.9        (9.3 to 30.3)",
            "Results 2: ",
            "  Arm/Group Title: Placebo + Exemestane",
            "  Arm/Group Description: Placebo and Exemestane: Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week plus exemestane (25 mg) administered orally once per day",
            "  Overall Number of Participants Analyzed: 59",
            "  Median (95% Confidence Interval)",
            "  Unit of Measure: weeks  10.7        (8.1 to 16.1)"
        ]
    },
    "9e28c807-8d88-4eea-87ee-48a42bd002ab": {
        "Section_id": "adverse_events",
        "Statement": "the primary trial and the secondary trial only record 4 of the same adverse events.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 10/14 (71.43%)",
            "  Hemoglobin 2/14 (14.29%)",
            "  Lymphopenia 1/14 (7.14%)",
            "  Cardiac ischemia/infarction 1/14 (7.14%)",
            "  Hypertension 2/14 (14.29%)",
            "  Hypotension 1/14 (7.14%)",
            "  Constipation 1/14 (7.14%)",
            "  Diarrhea 1/14 (7.14%)",
            "  Heartburn/dyspepsia 1/14 (7.14%)",
            "  Fatigue (asthenia, lethargy, malaise) 2/14 (14.29%)",
            "  Rigors/chills 1/14 (7.14%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 96/162 (59.26%)",
            "  Cardiac disorders - Other, specify 2/162 (1.23%)",
            "  Diarrhea 1/162 (0.62%)",
            "  Mucositis oral 2/162 (1.23%)",
            "  Nausea 1/162 (0.62%)",
            "  Fatigue 6/162 (3.70%)",
            "  Breast infection 2/162 (1.23%)",
            "  Soft tissue infection 1/162 (0.62%)",
            "  Lymphocyte count decreased 2/162 (1.23%)",
            "  Neutrophil count decreased 78/162 (48.15%)",
            "  Hypertension 1/162 (0.62%)"
        ]
    },
    "9f2fd0cc-af87-433d-9d2f-6235591d6cb1": {
        "Section_id": "results",
        "Statement": "Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee was highest in cohort 2.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Outcome Measurement: ",
            "  Percentage of Participants With Clinical Objective Response (cOR) in the Breast, Evaluated by an Independent Radiological Evaluation Monitoring Committee",
            "  cOR is defined as the documented evidence of complete response (CR) and partial response (PR) as assessed by ultrasound examination using Response Evaluation Criteria In Solid Tumors (RECIST). CR is defined as the disappearance of all target lesions (TLs) and non-TLs and the appearance of no new lesions (NLs). PR for TLs is defined as a >=30% decrease in the sum of the longest diameter (LD) of TLs, taking as a reference the Baseline sum LD. For non-TLs, it is defined as the persistence of >=1 non-TL and no new TLs or non-TLs.",
            "  Time frame: From Baseline (Day 1) up to 6 months, evaluated every 12 weeks",
            "Results 1: ",
            "  Arm/Group Title: Letrozole + Placebo",
            "  Arm/Group Description: Letrozole tablets in the dose of 2.5 milligrams (mg) plus matching placebo were administered orally once daily for 6 months prior to surgery.",
            "  Overall Number of Participants Analyzed: 48",
            "  Measure Type: Number",
            "  Unit of Measure: percentage of participants  CR: 2",
            "PR: 58",
            "Results 2: ",
            "  Arm/Group Title: Letrozole + Lapatinib",
            "  Arm/Group Description: Letrozole tablets in the dose of 2.5 mg plus lapatinib ditosylate monohydrate tablets in the dose of 1500 mg were administered orally once daily for 6 months prior to surgery.",
            "  Overall Number of Participants Analyzed: 41",
            "  Measure Type: Number",
            "  Unit of Measure: percentage of participants  CR: 12",
            "PR: 54"
        ]
    },
    "a6682883-ace7-4d83-a35c-956928fdc75a": {
        "Section_id": "eligibility",
        "Statement": "the secondary trial and the primary trial do not require participants to be of a particular ethnicity, sex, height or to be able to speak a specific language.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Inclusion criteria:",
            "  Female patients >=18 years with proven diagnosis of HER2-overexpressing, histologically confirmed breast cancer",
            "  Locally advanced or metastatic disease",
            "  Must have disease that can be evaluated according to RECIST 1.1 (Response Evaluation Criteria for Solid Tumours version 1.1)",
            "  For trastuzumab pre-treated patients, must have failed prior trastuzumab treatment",
            "  Investigator-confirmed diagnosis of Inflammatory Breast Cancer",
            "  Must have biopsiable disease",
            "Exclusion criteria:",
            "  Prior treatment with HER2-targeted small molecules or antibodies other than trastuzumab (which must have been given in the trastuzumab-failure study population)",
            "  Must not have received prior vinorelbine treatment"
        ],
        "Secondary_CT": [
            "INCLUSION CRITERIA:",
            "  Postmenopausal female.",
            "  Postmenopausal defined as no menses for at least 12 months or bilateral oophorectomy. In unclear cases, (e.g. 50 year old who has had hysterectomy) chemical confirmation of postmenopausal status may be confirmed with follicle stimulating hormone (FSH) greater than 35 U/L.",
            "  Elevated risk for developing invasive breast cancer by virtue of one of the following criteria:",
            "  Gail Model risk of greater than or equal to 1.7% over 5 years from study entry. (This is the same minimum level of risk required for a subject to be eligible for the recently completed NSABP-P1 tamoxifen breast cancer prevention trial).",
            "  Lobular neoplasia.",
            "  Atypical ductal hyperplasia.",
            "  DCIS (ductal carcinoma in situ) that has been previously treated with mastectomy or lumpectomy and radiation, +/- tamoxifen.",
            "  Deleterious mutations in BRCA1 or 2 OR A priori risk assessment of 20% chance or greater of carrying BRCA1/2 gene mutation. The BRCAPRO and Couch model will both be used to asses this risk. If a woman has a 20% risk of carrying a BRCA1/2 mutation by either model, she will meet eligibility criteria.",
            "  Prior stage I or II breast cancer at least 2 years out from treatment for invasive disease and no prior use of aromatase inhibitors.",
            "  Subjects should be willing to abstain from use of hormonal therapies (e.g. tamoxifen, hormone replacement therapy, oral contraceptive pills, hormone-containing intrauterine devices (IUDs). E-string is acceptable). Venlafaxine will be offered as supportive care for women with menopausal symptoms.",
            "  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.",
            "  Subject has been counseled regarding her options and has signed the informed consent document.",
            "  Baseline dual-emission x-ray absorptiometry (DEXA) scan with bone mineral density (BMD) T-score greater than or equal to 2.5 at antero posterior (AP) spine.",
            "  Hemoglobin greater than or equal to 11 g/dl.",
            "  Creatinine less than 1.5 times the upper limits of normal.",
            "  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) less than 2.5 times upper limit of normal.",
            "  No investigational agent for the past 30 days.",
            "  If history of cancer (other than squamous or basal cell skin cancers), subject must have no evidence of disease at time of enrollment AND no history of cancer directed treatment in the 2 years preceding enrollment.",
            "EXCLUSION CRITERIA:",
            "  Current or recent chronic use (within 3 months) of hormonal medications, e.g. oral contraceptive pills, hormone replacement therapy, tamoxifen, raloxifene, IUD with progestins or corticosteroids. (Subjects on chronic topical or inhaled steroids will be eligible for the study.) Current use of phenytoin, carbamazepine, rifampin due to increased estrogen metabolism.",
            "  History of clotting or bleeding disorder.",
            "  History of allergic reactions attributed to compounds of similar chemical or biologic composition to exemestane (e.g. anastrozole, letrozole, formestane).",
            "  Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."
        ]
    },
    "a7903e59-9620-457a-8d83-eb6eb5dd8a2b": {
        "Section_id": "adverse_events",
        "Statement": "At least 1 participant in each cohort of the primary trial showed signs of poor liver function.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 4/109 (3.67%)",
            "  Anaemia * 0/109 (0.00%)",
            "  Haemolytic uraemic syndrome * 0/109 (0.00%)",
            "  Leukopenia * 0/109 (0.00%)",
            "  Cardiac failure * 0/109 (0.00%)",
            "  Pyrexia * 1/109 (0.92%)",
            "  Hepatic function abnormal * 1/109 (0.92%)",
            "  Arthritis bacterial * 0/109 (0.00%)",
            "  Lung infection * 0/109 (0.00%)",
            "  Haemoglobin decreased * 1/109 (0.92%)",
            "  Neutrophil count decreased * 0/109 (0.00%)",
            "Adverse Events 2:",
            "  Total: 9/110 (8.18%)",
            "  Anaemia * 1/110 (0.91%)",
            "  Haemolytic uraemic syndrome * 0/110 (0.00%)",
            "  Leukopenia * 0/110 (0.00%)",
            "  Cardiac failure * 1/110 (0.91%)",
            "  Pyrexia * 2/110 (1.82%)",
            "  Hepatic function abnormal * 0/110 (0.00%)",
            "  Arthritis bacterial * 2/110 (1.82%)",
            "  Lung infection * 0/110 (0.00%)",
            "  Haemoglobin decreased * 1/110 (0.91%)",
            "  Neutrophil count decreased * 0/110 (0.00%)"
        ]
    },
    "aa6a20f8-ee49-42b7-9b9b-64caa8b22e35": {
        "Section_id": "adverse_events",
        "Statement": "Only 2 of the 12 adverse event types recorded in the primary trial, occurred more than once.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 10/33 (30.30%)",
            "  Constipation 1/33 (3.03%)",
            "  Dysphagia 1/33 (3.03%)",
            "  Ileus 1/33 (3.03%)",
            "  Nausea 1/33 (3.03%)",
            "  Vomiting 1/33 (3.03%)",
            "  Fatigue 1/33 (3.03%)",
            "  Pain 1/33 (3.03%)",
            "  Sepsis 2/33 (6.06%)",
            "  Urinary tract infection 1/33 (3.03%)",
            "  Alanine aminotransferase increased 1/33 (3.03%)",
            "  Aspartate aminotransferase increased 1/33 (3.03%)",
            "  Dehydration 2/33 (6.06%)"
        ]
    },
    "b059e44b-9830-4c45-858e-ebd007fbaf69": {
        "Section_id": "adverse_events",
        "Statement": "Cohort 1 and 2 of the primary trial recorded the same number of patients with Febrile Neutropenia.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 5/41 (12.20%)",
            "  Neutropenia  4/41 (9.76%)",
            "  Febrile Neutropenia  0/41 (0.00%)",
            "  SGPT (ALT)  1/41 (2.44%)",
            "Adverse Events 2:",
            "  Total: 5/40 (12.50%)",
            "  Neutropenia  4/40 (10.00%)",
            "  Febrile Neutropenia  1/40 (2.50%)",
            "  SGPT (ALT)  0/40 (0.00%)"
        ]
    },
    "b4c97206-66fd-468b-8388-fac076222c10": {
        "Section_id": "adverse_events",
        "Statement": "There were 7 more cases of Anaemia and 1 more case of Disseminated intravascular coagulation in cohort 1 of the primary trial compared to cohort 2.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 158/482 (32.78%)",
            "  Anaemia 7/482 (1.45%)",
            "  Disseminated intravascular coagulation 1/482 (0.21%)",
            "  Lymphadenopathy 0/482 (0.00%)",
            "  Neutropenia 0/482 (0.00%)",
            "  Thrombocytopenia 2/482 (0.41%)",
            "  Anaemia 28/482 (1.66%)",
            "  Disseminated intravascular coagulation 21/482 (0.21%)",
            "  Febrile neutropenia 21/482 (0.21%)",
            "  Lymphadenopathy 20/482 (0.00%)",
            "  Neutropenia 20/482 (0.00%)",
            "Adverse Events 2:",
            "  Total: 37/238 (15.55%)",
            "  Anaemia 2/238 (0.84%)",
            "  Disseminated intravascular coagulation 0/238 (0.00%)",
            "  Lymphadenopathy 1/238 (0.42%)",
            "  Neutropenia 1/238 (0.42%)",
            "  Thrombocytopenia 0/238 (0.00%)",
            "  Anaemia 22/238 (0.84%)",
            "  Disseminated intravascular coagulation 20/238 (0.00%)",
            "  Febrile neutropenia 21/238 (0.42%)",
            "  Lymphadenopathy 21/238 (0.42%)",
            "  Neutropenia 21/238 (0.42%)"
        ]
    },
    "c6fc8336-7c74-443e-9548-3bbafe21fc37": {
        "Section_id": "results",
        "Statement": "In total Less than 10% of patients in the primary trial either had a disease relapse or died.",
        "Label": "Entailment",
        "Primary_CT": [
            "Outcome Measurement: ",
            "  Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years",
            "  Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.",
            "  Time frame: Baseline (Month 0) up to 2.75 years",
            "Results 1: ",
            "  Arm/Group Title: Exemestane",
            "  Arm/Group Description: Exemestane (Aromasin  ) 25 mg QD for 5 years.",
            "  Overall Number of Participants Analyzed: 4898",
            "  Measure Type: Number",
            "  Unit of Measure: Events (disease relapse or death)  352",
            "Results 2: ",
            "  Arm/Group Title: Tamoxifen Followed by Exemestane",
            "  Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.",
            "  Overall Number of Participants Analyzed: 4868",
            "  Measure Type: Number",
            "  Unit of Measure: Events (disease relapse or death)  388"
        ]
    },
    "d22f01f0-b2be-45b9-8996-11727750b91e": {
        "Section_id": "intervention",
        "Statement": "the primary trial participants receive more anastrozole, Fulvestrant and exemestane than patients in the secondary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  Treatment (Vorinostat, AI Therapy)",
            "  Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.",
            "  vorinostat: Given PO",
            "  anastrozole: Given PO",
            "  letrozole: Given PO",
            "  exemestane: Given PO",
            "  positron emission tomography: Correlative studies",
            "  F-18 16 alpha-fluoroestradiol: Correlative studies",
            "  fludeoxyglucose F 18: Correlative studies",
            "  laboratory biomarker analysis: Correlative studies"
        ],
        "Secondary_CT": [
            "INTERVENTION 1: ",
            "  Fulvestrant 250 mg + Tipifarnib 300 mg",
            "  Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity"
        ]
    },
    "d97c3981-50f9-4221-aec6-60661b831c8e": {
        "Section_id": "eligibility",
        "Statement": "A 56 year old patient presenting occasional memory loss would be excluded from both the secondary trial and the primary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Inclusion Criteria:",
            "  Receiving any treatment for breast cancer or have completed acute treatment for breast cancer < 10 years ago",
            "  Attending clinic visits in the course of follow-up care (i.e., not an initial consult visit)",
            "  Willing to have clinic visit audio recorded",
            "Exclusion Criteria:",
            "  Unable to speak English",
            "  Eastern Cooperative Oncology Group (ECOG) Performance score > 2 OR too ill to participate as judged by physician, self-report, or observation of the research team member",
            "  Overt cognitive dysfunction or psychiatric disturbance or severe mental illness (e.g., dementia, suicidal behavior, or psychosis), as observed or judged by the researcher or referring source."
        ],
        "Secondary_CT": [
            "Inclusion Criteria - Phase 1 (Cohort A):",
            "  Female patient  18 years",
            "  Patient must be postmenopausal, verified by 1 of the following:",
            "  Bilateral surgical oophorectomy",
            "  No spontaneous menses > 1 year",
            "  No menses for < 1 year with FSH and estradiol levels in postmenopausal range. If a study subject under the age of 60 reports prior surgery in which the ovaries were removed and if the operative report cannot be obtained to confirm bilateral salpingo-oophorectomy, the subject will have serum estradiol, LH and FSH drawn to confirm menopausal status prior to study entry",
            "  Postmenopausal women with primary invasive breast cancer, histologically confirmed by core needle (or incisional biopsy), whose tumors are estrogen (ER) and/or progesterone (PgR) positive. Estrogen- and/or progesterone-receptor positive disease based on 10% or more nuclear staining of the invasive component of the tumor",
            "  Stage IV disease (as defined by the AJCC Staging Manual, 6th Edition, 2002); or locally relapsed, unresectable disease",
            "  Measurable or evaluable disease according to RECIST criteria (see appendix VII)",
            "  Both HER2-positive and HER2-negative disease (as defined by IHC or by fluorescence in situ hybridization [FISH]). HER2+ must have had prior treatment with trastuzumab and/or lapatinib.",
            "  ECOG performance status 0-2 (see appendix VI)",
            "  Patients are suitable candidates for treatment with anastrozole (patients may have had any prior endocrine therapy or prior chemotherapy for treatment of their disease, either as adjuvant therapy, or as treatment for advanced disease). There is no restriction on the number of prior regimens in the phase I cohort A.",
            "  Patient is accessible and willing to comply with treatment and follow-up",
            "  Patient is willing to provide written informed consent prior to the performance of any study-related procedures",
            "  Required laboratory values",
            "  Absolute neutrophil count  to 1.5 x 10^9/L",
            "  Hemoglobin  to 9.0 g/dL",
            "  Platelet count  to 100 x 10^9/L",
            "  Creatinine  1.5 mg/dL",
            "  Total bilirubin  1.0 x upper limit of normal (ULN)",
            "  Alkaline phosphatase and AST/ALT within protocol parameters. In determining eligibility, the more abnormal of the two values (AST or ALT) should be used.",
            "  Inclusion Criteria - Phase 2 (Cohort B):",
            "  Female patient  18 years",
            "  Patient must be postmenopausal, verified by 1 of the following:",
            "  Bilateral surgical oophorectomy",
            "  No spontaneous menses  1 year",
            "  No menses for < 1 year with FSH and estradiol levels in postmenopausal range. If a study subject under the age of 60 reports prior surgery in which the ovaries were removed and if the operative report cannot be obtained to confirm bilateral salpingo-oophorectomy, the subject will have serum estradiol, LH and FSH drawn to confirm menopausal status prior to study entry",
            "  Postmenopausal women with primary invasive breast cancer, histologically confirmed by core needle (or incisional biopsy), whose tumors are estrogen (ER) and/or progesterone (PgR) positive. Estrogen- and/or progesterone-receptor positive disease based on 10% or more nuclear staining of the invasive component of the tumor. Patients may have bilateral or multifocal invasive breast cancers. The patient may have concurrent DCIS in either breast but the DCIS will not be measured as part of the study endpoints.",
            "  Tumor size  2 cm",
            "  Tumor measurable either by clinical examination, mammography, MRI, or ultrasound",
            "  HER2-negative disease (as defined by fluorescence in situ hybridization [FISH] or by IHC)",
            "  ECOG performance status 0-1 (see Appendix VI)",
            "  Patient is accessible and willing to comply with treatment and follow-up",
            "  Patient is willing to provide written informed consent prior to the performance of any study-related procedures",
            "  Required laboratory values",
            "  Absolute neutrophil count  1.5 x 10^9/L",
            "  Hemoglobin  9.0 g/dL",
            "  Platelet count  70 x 10^9/L",
            "  Creatinine  1.5 mg/dL",
            "  Total bilirubin  1.5 x upper limit of normal (ULN)",
            "  Alkaline phosphatase and AST/ALT  1.5 x upper limit of normal (ULN)",
            "  Exclusion Criteria - Phase 1 (Cohort A):",
            "  Concurrent therapy with any other non-protocol anti-cancer therapy",
            "  Any agent with estrogenic or putatively estrogenic properties, including herbal preparations, must be stopped at least one week prior to registration.",
            "  Ongoing, chronic administration of bisphosphonate therapy is allowed so long as such treatment was ongoing at the time of study entry.",
            "  Current therapy with hormone replacement therapy, or any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (agents must be stopped prior to randomization)",
            "  Presence of neuropathy  grade 2 (NCI-CTC version 3.0) at baseline",
            "  History of any other malignancy within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix",
            "  Clinically significant cardiovascular disease (e.g., hypertension [BP > 150/100], history of myocardial infarction or stroke within 6 months, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication",
            "  Active, uncontrolled infection requiring parenteral antimicrobials",
            "  A history of a severe hypersensitivity reaction to anastrozole, or AZD0530 or their excipients",
            "  Evidence of bleeding diathesis or coagulopathy.",
            "  Resting EKG with measurable QTc interval of >480msec at 2 or more time points within a 24 hr period.",
            "  Since AZD0530 is a substrate and inhibitor of CYP3A4, patients requiring medication with drugs listed in Appendix XI should be excluded from study.",
            "  Any evidence of severe or uncontrolled systemic medical or psychiatric conditions (e.g. Severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]) or current unstable or uncompensated respiratory or cardiac conditions which make it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol",
            "  Evidence of underlying pulmonary dysfunction as evidenced by oxygen saturation <90% by pulse oximetry, interstitial pulmonary infiltrates on high resolution CT scan prior to study entry and/or symptomatic pulmonary (pleural or parenchymal) metastasis.",
            "  Exclusion Criteria - Phase 2 (Cohort B):",
            "  Prior chemotherapy, endocrine therapy or radiotherapy for the presenting breast cancer. Prior incidence and treatment of contralateral invasive or non-invasive breast cancer is not an exclusion criterion.",
            "  Inflammatory breast cancer, clinically defined as the presence of erythema or induration involving one-third or more of the breast, or pathologically defined as dermal lymphatic invasion",
            "  Prior excisional biopsy or complete resection of the primary invasive tumor (prior sentinel node biopsy allowed)",
            "  Prior ipsilateral radiation therapy for invasive or non-invasive breast cancer",
            "  Distant metastasis is an exclusion criterion - Isolated ipsilateral supraclavicular node involvement and/or direct invasion of the primary tumor into skin is allowed",
            "  Concurrent therapy with any other non-protocol anti-cancer therapy",
            "  Any agent with estrogenic or putatively estrogenic properties, including herbal preparations, must be stopped at least one week prior to registration",
            "  Current therapy with hormone replacement therapy, or any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (agents must be stopped for one week prior to randomization)",
            "  Presence of neuropathy  grade 2 (NCI-CTC AE version 3.0) at baseline",
            "  History of any other malignancy within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix",
            "  Clinically significant cardiovascular disease (e.g. history of myocardial infarction or stroke within 6 months, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication",
            "  Active, uncontrolled infection requiring parenteral antimicrobials",
            "  A history of a severe hypersensitivity reaction to anastrozole, or AZD0530 (saracatinib) or their excipients",
            "  Evidence of bleeding diathesis or coagulopathy",
            "  Resting EKG with measurable QTc interval of >480msec at 2 or more time points within a 24 hr period.",
            "  AZD0530 (saracatinib) is a substrate and inhibitor of CYP3A4. Since concurrent administration of AZD0530 with other CYP3A4 substrates has been shown to be well tolerated, continuation or initiation of medically indicated drugs that are substrates of CYP3A4 is permitted at MD discretion. Drugs listed in Appendix X that are known to strongly induce or inhibit CYP3A4 activity should be discontinued prior to study entry and should not be initiated during protocol treatment.",
            "  Any evidence of severe or uncontrolled systemic psychiatric or medical conditions (eg. Severe hepatic impairment, interstitial lung disease [bilateral, diffuse, parenchymal lung disease]) or current unstable or uncompensated respiratory or cardiac conditions which make it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol",
            "  Evidence of underlying pulmonary dysfunction as evidenced by oxygen saturation <90% by pulse oximetry prior to study entry and/or symptomatic pulmonary (pleural or parenchymal) disease.",
            "  Subjects unwilling or unable to undergo breast MRI as required by protocol will be excluded from study"
        ]
    },
    "da1e1019-adb5-47bf-8093-e03352ca9e51": {
        "Section_id": "eligibility",
        "Statement": "Patients cannot do more than half an hour of physical exercise in a day, if they are to participate in the primary trial, however, this is not a requirement for the secondary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Inclusion Criteria:",
            "  Histologically confirmed stage I-III colorectal or breast cancer",
            "  Undergone curative-intent complete surgical resection and completed all adjuvant therapy (if indicated) at least 2 months prior to enrollment",
            "  Note: Breast cancer subjects on hormonal therapy or trastuzumab only therapy and colorectal cancer subjects on adjunctive therapies not considered cytotoxic chemotherapy (including those participating in CALGB 80702 receiving only celecoxib/placebo) are eligible.",
            "  Participants will be allowed to receive concomitant adjuvant endocrine therapy for breast cancer; however, all endocrine agents must be initiated at least 1 month prior to enrollment in the study and continued throughout the duration of study participation.",
            "  Less than 120 minutes of exercise per week",
            "  Approval by oncologist or surgeon",
            "  English speaking and able to read English",
            "  No planned surgery anticipated in the 3 month intervention period",
            "  At least one month from any major surgery to start of intervention including colostomy reversal",
            "Exclusion Criteria:",
            "  Concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in-situ cervical cancer)",
            "  Metastatic disease",
            "  Scheduled to receive any form of further adjuvant cancer therapy",
            "  Currently on medication for diabetes treatment",
            "  Pregnant or breast-feeding",
            "  Any condition associated with increased risk of metformin-associated lactic acidosis (prior renal failure or liver failure, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)",
            "  Known hypersensitivity or intolerance to metformin"
        ],
        "Secondary_CT": [
            "Inclusion Criteria:",
            "  The patient has provided written informed consent with HIPAA authorization before participating in the study, as has his/her responsible caregiver, if applicable.",
            "  The patient is a candidate for surgical intervention, with lymph node mapping being a part of the surgical plan.",
            "  The patient is at least 18 years of age at the time of consent.",
            "  The patient has an ECOG performance status of Grade 0 - 2 [8].",
            "  The patient has a clinical negative node status at the time of study entry.",
            "  If of child bearing potential, the patient has a negative pregnancy test within 72 hours prior to administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.",
            "  The patient is currently not participating in another investigational drug study.",
            "  Melanoma Patients",
            "  The patient has a diagnosis of primary melanoma.",
            "  Breast Cancer Patients",
            "  The patient has a diagnosis of primary breast cancer.",
            "  Patients with pure ductal carcinoma in situ (DCIS) or non-invasive carcinoma if lymph node biopsy is part of the surgical plan.",
            "Exclusion Criteria:",
            "  The patient is pregnant or lactating;",
            "  The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T,N0,M0);",
            "  The patient has a known hypersensitivity to Lymphazurin or Patent Bleu V.",
            "  Melanoma Patients",
            "  The patient has a tumor with a Breslow depth less than 0.75mm.;",
            "  Patients that have had preoperative chemotherapy, immunotherapy or radiation therapy;",
            "  Patients diagnosed with a prior invasive melanoma that would occur on the same body region or potentially draining to the same nodal basin or patients with truncal or extremity primary melanoma who has had a prior breast cancer potentially draining to the same axillary nodal basin;",
            "  Patients who have undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the primary melanoma;",
            "  Patients who have undergone a wide excision for their primary melanoma (>1 cm in dimension) or complex reconstruction (rotation, free flap or skin graft of any type).",
            "  Breast Cancer Patients",
            "  The patient has bilateral primary breast cancers or multiple tumors within their breast;",
            "  Patients that have had prior surgical procedures such as breast implants, reduction mammoplasty or axillary surgery;",
            "  Patients scheduled for bilateral mastectomy for any reason;",
            "  Patients that have had preoperative radiation therapy to the affected breast or axilla"
        ]
    },
    "db96c4d6-ffcd-401a-8af3-807f665f16f7": {
        "Section_id": "eligibility",
        "Statement": "Patients diagnosed with osteonecrosis are eligible for the primary trial but excluded from the secondary trial.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Inclusion criteria:",
            "  Female patients  18 years of age.",
            "  Written informed consent given.",
            "  Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed.",
            "  Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months.",
            "  Eastern Cooperative Oncology Group (ECOG) performance status 2 .",
            "  Life expectancy  1 year.",
            "Exclusion criteria:",
            "  More than 3 months since last infusion of Zoledronic Acid (Zometa\u00ae).",
            "  Treatments with other bisphosphonate than Zoledronic Acid (Zometa\u00ae) at any time prior to study entry.",
            "  Serum creatinine > 3 mg/dL (265 \u03bcmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85",
            "  Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L).",
            "  Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.",
            "  Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).",
            "  Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide).",
            "  History of non-compliance to medical regimens or potential unreliable behavior.",
            "  Known sensitivity to study drug(s) or class of study drug(s).",
            "  Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study",
            "  Use of any other investigational agent in the last 30 days."
        ],
        "Secondary_CT": [
            "Inclusion Criteria:",
            "  Post-menopausal women at high risk for development of breast cancer",
            "  On a stable dose of hormone replacement therapy",
            "  have cytomorphologic evidence of hyperplasia +/- atypia and Ki-67 expression >1.5% in benign breast epithelial cells acquired by RPFNA",
            "  Serum level of 25-OH vitamin D of at least 30 ng/ml prior to study entry",
            "  Willing to have a repeat random periareolar fine needle aspiration (RPFNA) and mammogram at 6 months and 12 months (if participating in the open label portion of the study) following initiation of study drug",
            "Exclusion Criteria:",
            "  Prior history of osteoporosis or osteoporotic fracture.",
            "  Prior history of invasive breast cancer or other invasive cancer within five years from date of study entry.",
            "  Current and chronic use of cyclooxygenase-2 (COX-2) specific inhibitors or NSAIDs",
            "  Receiving treatment for rheumatoid arthritis or fibromyalgia",
            "  Current history of poorly controlled migraines or perimenopausal symptoms",
            "  Currently receiving other investigational agents.",
            "  Receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane, letrozole, etc.) at any time in the past."
        ]
    },
    "e1417a26-2f40-4dd6-b598-e66e57312595": {
        "Section_id": "adverse_events",
        "Statement": "Less than 5% of cohort 1 of the primary trial had LACRIMAL DISORDER, 0% of the secondary trial patients were recorded as having LACRIMAL DISORDER.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 6/22 (27.27%)",
            "  Thrombocytopenia  1/22 (4.55%)",
            "  leucocytopenia  1/22 (4.55%)",
            "  neutropenia  1/22 (4.55%)",
            "  papilledema  1/22 (4.55%)",
            "  Nausea  1/22 (4.55%)",
            "  hyperglycemia  1/22 (4.55%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 24/101 (23.76%)",
            "  LYMPHADENOPATHY 0/101 (0.00%)",
            "  FEBRILE NEUTROPENIA 20/101 (0.00%)",
            "  ATRIAL FIBRILLATION 1/101 (0.99%)",
            "  ARRHYTHMIA 20/101 (0.00%)",
            "  CARDIAC FAILURE 22/101 (1.98%)",
            "  CARDIAC FAILURE CONGESTIVE 20/101 (0.00%)",
            "  CORONARY OSTIAL STENOSIS 20/101 (0.00%)",
            "  LACRIMAL DISORDER 0/101 (0.00%)",
            "  BLINDNESS 21/101 (0.99%)",
            "  GASTRIC ULCER 1/101 (0.99%)",
            "  NAUSEA 1/101 (0.99%)",
            "Adverse Events 2:",
            "  Total: 22/103 (21.36%)",
            "  LYMPHADENOPATHY 1/103 (0.97%)",
            "  FEBRILE NEUTROPENIA 21/103 (0.97%)",
            "  ATRIAL FIBRILLATION 1/103 (0.97%)",
            "  ARRHYTHMIA 21/103 (0.97%)",
            "  CARDIAC FAILURE 20/103 (0.00%)",
            "  CARDIAC FAILURE CONGESTIVE 21/103 (0.97%)",
            "  CORONARY OSTIAL STENOSIS 21/103 (0.97%)",
            "  LACRIMAL DISORDER 1/103 (0.97%)",
            "  BLINDNESS 20/103 (0.00%)",
            "  GASTRIC ULCER 0/103 (0.00%)",
            "  NAUSEA 0/103 (0.00%)"
        ]
    },
    "e5a4cb11-2a00-4144-93ba-f5462d7efbf0": {
        "Section_id": "intervention",
        "Statement": "In the primary trial and the secondary trial the only drugs administered orally are saracatinib and Veliparib.",
        "Label": "Entailment",
        "Primary_CT": [
            "INTERVENTION 1: ",
            "  Arm 1 (Paclitaxel, Carboplatin)",
            "  Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.",
            "  Paclitaxel: Given IV",
            "  Carboplatin: Given IV",
            "  Doxorubicin: Given IV",
            "  Cyclophosphamide: Given IV",
            "INTERVENTION 2: ",
            "  Arm 2 (Veliparib, Paclitaxel, Carboplatin)",
            "  Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.",
            "  Paclitaxel: Given IV",
            "  Carboplatin: Given IV",
            "  Doxorubicin: Given IV",
            "  Cyclophosphamide: Given IV",
            "  Veliparib: Given PO"
        ],
        "Secondary_CT": [
            "INTERVENTION 1: ",
            "  Treatment (Enzyme Inhibitor Therapy)",
            "  Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
        ]
    },
    "e6388dc2-b096-467d-8b70-fd5346dd581a": {
        "Section_id": "adverse_events",
        "Statement": "The highest number of occurences for any adverse event in both the primary trial and the secondary trial was 2.",
        "Label": "Entailment",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 39/2240 (1.74%)",
            "  Supraven.arrhyth. Atrial fibrillation 1/2240 (0.04%)",
            "  Cardiac ischemia/infarction 2/2240 (0.09%)",
            "  Valvular heart disease 1/2240 (0.04%)",
            "  Cardiac General - Other 2/2240 (0.09%)",
            "  Endocrine - Other 1/2240 (0.04%)",
            "  Ocular - Other 1/2240 (0.04%)",
            "  Colitis 2/2240 (0.09%)",
            "  Diarrhea 1/2240 (0.04%)",
            "  Dysphagia 1/2240 (0.04%)",
            "  Gastritis 1/2240 (0.04%)"
        ],
        "Secondary_CT": [
            "Adverse Events 1:",
            "  Total: 6",
            "  Agranulocytosis 0/42 (0.00%)",
            "  Anaemia 2/42 (4.76%)",
            "  Febrile neutropenia 1/42 (2.38%)",
            "  Leukopenia 0/42 (0.00%)",
            "  Neutropenia 1/42 (2.38%)",
            "  Thrombocytopenia 1/42 (2.38%)",
            "  Cardio-respiratory arrest 0/42 (0.00%)",
            "  Pericardial effusion 1/42 (2.38%)",
            "  Gastric ulcer haemorrhage 0/42 (0.00%)",
            "  Melaena 0/42 (0.00%)",
            "  Fatigue 1/42 (2.38%)",
            "  Multi-organ failure 0/42 (0.00%)",
            "Adverse Events 2:",
            "  Total: 13",
            "  Agranulocytosis 1/61 (1.64%)",
            "  Anaemia 1/61 (1.64%)",
            "  Febrile neutropenia 0/61 (0.00%)",
            "  Leukopenia 2/61 (3.28%)",
            "  Neutropenia 2/61 (3.28%)",
            "  Thrombocytopenia 1/61 (1.64%)",
            "  Cardio-respiratory arrest 1/61 (1.64%)",
            "  Pericardial effusion 0/61 (0.00%)",
            "  Gastric ulcer haemorrhage 1/61 (1.64%)",
            "  Melaena 1/61 (1.64%)",
            "  Fatigue 1/61 (1.64%)",
            "  Multi-organ failure 1/61 (1.64%)"
        ]
    },
    "eae76b80-107c-4469-b06f-73d5f7a4c1d5": {
        "Section_id": "eligibility",
        "Statement": "Heavy smokers (more than 5 cigarettes smoked per day) are eligible for the secondary trial and the primary trial.",
        "Label": "Entailment",
        "Primary_CT": [
            "Inclusion Criteria:",
            "  Female gender;",
            "  Age 18 years;",
            "  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1",
            "  Histologically confirmed invasive breast cancer:",
            "  Primary tumor greater than 1 cm diameter, measured by clinical examination and mammography or ultrasound.",
            "  Any N,",
            "  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed);",
            "  Over expression and/or amplification of HER2 in the invasive component of the primary tumor and confirmed by a certified laboratory prior to randomization.",
            "  Known hormone receptor status.",
            "  Hematopoietic status:",
            "  CBC not less than .75 of institutional lower limit. Absolute neutrophil count  1,5 x 10^9/L, Platelet count  100 x 10^9/L, Hemoglobin at least 9 g/dl,",
            "  Hepatic status:",
            "  Serum total bilirubin  2 x upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (< 1.5 x ULN) is allowed, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT)  3.5 times ULN, Alkaline phosphatase  2.5 times ULN,  Renal status: Creatinine  1.5mg/dL,",
            " Cardiovascular: Baseline left ventricular ejection fraction (LVEF) \u00b3 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan,",
            "  Negative serum or urine \u03b2-hCG pregnancy test at screening for patients of childbearing potential within 2-weeks (preferably 7 days) prior to randomization.",
            "  Fertile patients must use effective contraception (barrier method - condoms, diaphragm - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable, or implant hormonal contraceptives are not allowed)",
            "  Signed informed consent form (ICF)",
            "  Patient accepts to make available tumor samples for submission to central laboratory to conduct translational studies as part of this protocol.",
            "Exclusion Criteria:",
            "  Previous (less than 5 years) or current history of malignant neoplasms, except for curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ of the cervix.",
            "  Patients with a prior malignancy diagnosed more than 5 years prior to randomization may enter the study.",
            "  Preexisting peripheral neuropathy  grade 2",
            "  Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled hypertension (  180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen;",
            "  Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject's safety;",
            "  Unresolved or unstable, serious adverse events from prior administration of another investigational drug;",
            "  Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF;",
            "  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded;",
            "  Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies);",
            "  Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial;",
            "  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trastuzumab Emtansine, trastuzumab, lapatinib, paclitaxel, abraxane or their components;",
            "  Pregnant or lactating women;",
            "  Concomitant use of CYP3A4 inhibitors or inducers",
            "  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol",
            "  Patients have an active infection and require IV or oral antibiotics.",
            "  Pregnant or breast-feeding women",
            "  Patients unwilling or unable to comply with the protocol"
        ],
        "Secondary_CT": [
            "Inclusion Criteria :",
            "  women with primary breast cancer, without ongoing support for substance use.",
            "  An AUDIT-C score >1 or more than one cigarette smoked per day.",
            "  Individuals able to consent to benefit of intervention focused on substance use. (Karnofsky Index >70).",
            "  Exclusion Criteria :",
            "  Patients who currently use substances for which a second-line care is already committed.",
            "  Patients with a Karnofsky index <70."
        ]
    },
    "fb43432d-6c1b-4ff7-aea8-72bc2519a12d": {
        "Section_id": "adverse_events",
        "Statement": "Nobody in cohort 1 of the primary trial suffered from Hyperbilirrubinemia.",
        "Label": "Contradiction",
        "Primary_CT": [
            "Adverse Events 1:",
            "  Total: 23/436 (5.28%)",
            "  Neutropenia G 3; Leucopenia G2 1/436 (0.23%)",
            "  Hyperbilirrubinemia  [1]1/436 (0.23%)",
            "  Supraventricular arrhythmia NOS  [2]1/436 (0.23%)",
            "  Heart failure  [2]0/436 (0.00%)",
            "  Infarction and cardiac arrest 0/436 (0.00%)",
            "  Ischemia cardiac/Infarction  [3]1/436 (0.23%)",
            "  Coronary vasospam  [3]1/436 (0.23%)",
            "  Gastroenteritis and renal insuficience 1/436 (0.23%)",
            "Adverse Events 2:",
            "  Total: 6/425 (1.41%)",
            "  Neutropenia G 3; Leucopenia G2 0/425 (0.00%)",
            "  Hyperbilirrubinemia  [1]0/425 (0.00%)",
            "  Supraventricular arrhythmia NOS  [2]0/425 (0.00%)",
            "  Heart failure  [2]1/425 (0.24%)",
            "  Infarction and cardiac arrest 1/425 (0.24%)",
            "  Ischemia cardiac/Infarction  [3]0/425 (0.00%)",
            "  Coronary vasospam  [3]0/425 (0.00%)",
            "  Gastroenteritis and renal insuficience 0/425 (0.00%)"
        ]
    }
}